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INTRODUCTION 
Diabetes mellitus is one of the major public health burden leading to 
increased mortality. It is a metabolic disorder of multiple aetiologies characterized 
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism due to abnormalities in insulin production1. DM is also characterised 
by insulin resistance and pancreatic β cell dysfunction. Other factors predispose to 
type 2 Diabetes Mellitus are genetic variation, ageing, sedentary life style and 
obesity. In 2000, there were around 171 million diabetes cases and it is estimated 
that the number will double by 2030. A leading non communicable disease with 
multiple aetiologies, affects more than 100 million people worldwide and is 
considered as one of the five leading causes of death in the world. It is estimated 
that more than 62 million people are currently diagnosed with diabetes mellitus 
and is rapidly attaining the potential epidemic in India2. It has been reported that 
India (31.7 million) topped the world with the highest diabetic patients followed 
by China (20.8 million) and US (7.7 million) 3. 
Ancient literature has explained the use of various herbs in the treatment of 
diabetes mellitus. Many investigations of oral anti-hyperglycaemic agents of plant 
origin used in traditional medicine have been conducted and many plants have 
been found to show positive activity. Various animal models like genetic models, 
fat-fed diet model, and chemical induced diabetes model are available with their 
own advantages. STZ/Alloxan induced diabetic model is the one which is 
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commonly used in experiments. The emerging ideal model for anti-diabetic 
activity is STZ-Nicotinamide induced model since has the advantage of reduction 
in mortality4. Diabetes has become the trending disease; various folk medicines 
with several kinds of herbs are consumed and is also recommended for the 
management of Diabetes mellitus. 
Tephrosia purpurea Linn is a pan tropical, polymorphic, perennial herb 
belongs to the family fabacae popularly known as Saraphunkha in Sanskrit, Purple 
tephrosia in English with medicinal properties. Aqueous and ethanolic extract of 
seeds has anti-hyperglycaemic activity. Though there are many studies available, 
lack of information on utility of whole plant extract of Tephrosia purpurea in 
treatment of diabetes and their safety in renal and hepatic profile. Hence the 
present study is designed to explore the anti-diabetic activity and its safety in STZ- 
Nicotinamide induced diabetic rats. 
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AIM AND OBJECTIVES 
AIM: 
The aim of the study was to evaluate the anti-diabetic activity of whole 
plant extract of Tephrosia purpurea on STZ – Nicotinamide induced diabetes in 
Albino Wistar Rats 
 
OBJECTIVES: 
Primary Objective: 
 To study the antidiabetic activity of ethanolic extract of Tephrosia 
purpurea whole plant against STZ – Nicotinamide induced diabetes in 
Wistar rats  
 
 
Secondary Objective: 
 To assess the safety of ethanolic extract of Tephrosia purpurea whole plant 
on lipid profile, liver function and renal function test. 
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REVIEW OF LITERATURE 
Definition: 
As per WHO “ The term diabetes mellitus describes a metabolic disorder of 
multiple aetiology characterised by chronic hyperglycaemia with disturbances in 
carbohydrates, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both”5 
ADA defined as Diabetes is a group of metabolic diseases characterized by 
hyperglycaemia resulting from defects in insulin secretion, Insulin action or both.6 
History: 
Diabetes mellitus has been known since antiquity. During the ancient 
period, poor knowledge of anatomy, Pathophysiology and lack of diagnostic tools 
the disease remained uncertain. 
Ancient literatures Papyrus also mentioned about the distinctive features of 
patients suffering from diabetes and various treatment modalities. In 1500 BC, 
Ebers Papyrus described about the patient suffering from excessive thirst, 
increased urination and they were treated by extracts of herbal plant. In 2000 BC, 
Kahun Papyrus mentioned just the title of a recipe for the “treatment of thirsty 
woman” but there is no text7. In 1st century AD Rufus of Epherus and Galen 
mentioned about the symptoms of Diabetes. During the 2nd century AD, the term 
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“Diabetes” was introduced by Aretaneus in the medical nomenclature. Diabetes in 
Greek verb (diabaino) which means “I pass through” 8 
Thomas Willis coined the term “Mellitus” in 17th century which means 
sweetness in the urine9. The glycogenic action of the liver and role of pancreas in 
the pathophysiology was discovered by Claude Bernard in 19th century10. In the 
year 1889, Oskar Minkowski and Joseph Von Mering demonstrated that Pancreas 
is important for the maintenance of glucose homeostasis that was the turning 
point11. In the 20th century Banting and Best after performing several experiments 
in the dog, they discovered insulin12. In the year 1922, first insulin was 
administered to human. The discovery of insulin saved millions of lives and in 
1923 they were awarded Nobel Prize in medicine13. The quest for oral anti-
diabetic drugs began in the backdrop of the discovery of insulin14. In the year 
1926, anti-hyperglycaemic moiety guanidine was isolated from the herbal plant 
Galega officinalis that marked the journey of oral anti diabetic agents. First 
synthesis of dimethyl biguanide (Metformin) is attributed to Werner and Bell in 
1922 and it was Sterne’s work that studied the mechanism of metformin in 
detail14.  It was serendipity when Janbon, a French physician and his colleagues 
confirmed hypoglycaemia in patients treated with P-Amino sulphonamide 
isopropyl thiodiazole for typhoid in 1942. Further establishment of activity this 
group of drugs was in the year 1946, Lobaitres and his colleagues explained that 
these drugs stimulate β cell release of insulin15. Thiazolidinedione were discovered 
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in late 1970 when clofibrates like Ciglitazone given to patients with type 2 DM 
was found to have hypoglycaemic activity. Acarbose was isolated in 1975 from 
the strains of actinoplanes species and synthesized in laboratory and found to be 
the inhibitor of α glucosidase16. 
Epidemiology: 
Diabetes is on the rise, it is no longer a disease of predominantly rich 
nations. The prevalence of diabetes is steadily increasing everywhere, most 
markedly in low and middle - income countries due to urbanization and rapid 
change of life style. Globally, an estimated 422 million adults were living with 
diabetes in 2014, compared to 108 million in 198017. The worldwide prevalence of 
DM has risen dramatically over the past two decades and has nearly doubled from 
4.7% to 8.5% since 1980 in the adult population.  
Over 90% of the diabetic population are suffering from type 2 diabetes 
mellitus and only about 5% have type 1 diabetes mellitus. Type 2 Diabetes already 
causes 5 million deaths per year, mostly from cardiovascular diseases and by 2030 
it is expected to be 7th leading cause of death globally18. Although the prevalence 
of both type 1 and type 2 DM is rising much more rapidly presumably because of 
increasing obesity, reduced activity because of industrialization and the aging of 
the population. The prevalence is highest in Middle East and North Africa17. 
 
12 | P a g e  
 
DM is fast gaining the status of potential epidemic in India with more than 
62 million individuals currently diagnosed with the disease. It is predicted that by 
2030 diabetes mellitus may afflict up to 79.4 million individuals in India19. It is 
estimated that the prevalence of DM in rural population is one quarter that of 
urban population for India. 
 
Classification of Diabetes Mellitus20 
 Type 1 Diabetes mellitus (Juvenile onset diabetes) 
 Immune mediated 
 Idiopathic 
 Type 2 Diabetes Mellitus ( Adult onset diabetes) 
 Type 3 Other types of Diabetes Mellitus 
 Genetic defects in the beta cell development or function: Mutation in 
MODY (1-6), mitochondrial DNA, Pro insulin/ Insulin Mutation, 
Mutation in other pancreatic islet regulator/Protein. 
 Genetic defects in insulin action: Type A insulin resistance, 
Leprachaunism, Rabson –Mendhall Syndrome, Lipodystrophy 
Syndrome. 
 Diseases of the pancreas: Pancreatitis, Cystic fibrosis, 
Hemochromatosis. 
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 Excess amount of counter regulatory hormones: Glucaganoma, 
Somatostatinoma, Cushing’s syndrome, Aldosteronoma, 
Phaeochromocytoma. 
 Infections: Congenital Rubella, CMV, Cox Sackie Virus. 
 Rare autoimmune disorders: Anti-Insulin receptor antibodies, Stiff- 
person syndrome. 
 Genetic syndromes: Down’s syndrome, Laurence Moon Biedl 
syndrome, Huntington’s chorea. 
 Type 4 Gestational Diabetes Mellitus 
Aetiology and Risk factors: 
Diabetes either Type 1 or Type 2, has equally strong genetic and 
environmental risk factors, an interaction of which leads to the clinical expression 
of the disease. Type 1 or Insulin dependent diabetes mellitus (IDDM) is often 
genetically-associated and immune-mediated. Individuals with IDDM have an 
absolute deficiency in insulin secretion and can be identified by serological 
evidence of autoimmune-mediated destruction of pancreatic islets or by genetic 
markers. However, this form of diabetes only accounts for 5-10% of those with 
diabetes. Also known as juvenile-onset diabetes, the rate of β-cells destruction in 
this form of diabetes is usually rapid in infants and children. However, it can occur 
at any age, even as late as eighties or nineties in life. Markers responsible for this 
destruction include islet cell autoantibodies (ICAs), insulin autoantibodies (IAAs), 
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glutamic acid decarboxylase autoantibodies (GAD65), and autoantibodies to 
tyrosine phosphatase IA-2 and IA-2α21. One and more of these autoantibodies are 
present in 85-90% of individuals when fasting hyperglycaemia is initially 
detected. Possibility of some aspect of diet and viral infection triggering an 
autoimmune exposure causing specific destruction of β-cells of the pancreas has 
been proposed. There is another form of IDDM where the pathogenicity is less 
well understood and hence known as idiopathic diabetes. Individuals in this 
category usually have permanent insulinopenia but lack signs of autoimmunity. 
This form of diabetes is strongly inherited. Hormone replacement therapy is not 
absolutely necessary for survival in this case as the degree of β-cell dysfunction 
varies among individuals22.  
The most common type of diabetes, Type 2 Diabetes mellitus or Non- 
Insulin dependent Diabetes mellitus (NIDDM) accounts for 90-95% of those with 
diabetes and has more complex aetiopathology. Individuals in this category can 
either have predominant insulin resistance with relative insulin deficiency or 
predominant insulin secretory defect with insulin resistance. The aetiology of this 
form of diabetes is wide and complicated, ranging from abnormalities in 
lipoprotein metabolism, central or visceral obesity, to cardiovascular risk factors 
such as hypertension. However, pancreatic islets destruction does not occur in 
NIDDM. On the contrary, insulin resistance may cause patient to have normal or 
even higher level of insulin. This form of diabetes is always associated with 
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obesity. It’s becoming more common in developed and developing countries, 
afflicting younger generations victimized by a global epidemic of overweight and 
obesity23. There is another type of diabetes diagnosed during pregnancy named 
gestational diabetes. Most of the cases resolve with delivery, but the condition 
may persist in some cases as unrecognized glucose intolerance may have begun 
before the pregnancy. 
Risk factors20:     
 Family history of diabetes  
 Obesity ( BMI > 25kg/m2) 
 Physical inactivity 
 Race/ Ethnicity ( Africo American , Latino, Native Americans, Asian 
American, Pacific Islander) 
 Previously identified with Impaired fasting glucose, Impaired glucose 
tolerance or on HbA1C 5.7-6.4% 
 History of GDM or delivery of Big baby >4kg 
 Hypertension ( BP >140/90mm Hg) 
 HDL Cholesterol level <35mg/dl ; Triglycerides level >250mg/dl 
 History of polycystic ovarian syndrome 
 Previous history of cardiovascular disease 
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ADA Diagnosis Criteria6 
 
The American Diabetes Association (ADA) criteria for the diagnosis 
of diabetes are any of the following:  
 A HbA1c level of 6.5% or higher; the test should be performed in a 
laboratory using a method that is certified by the National Glycohemoglobin 
Standardization Program (NGSP) and standardized or traceable to the 
Diabetes Control and Complications Trial (DCCT) reference assay, or 
 A fasting plasma glucose (FPG) level of 126 mg/dl (7 mmol/L) or higher, or 
 A 2-hour plasma glucose level of 200 mg/dl (11.1 mmol/L) or higher during 
a 75-g oral glucose tolerance test (OGTT), or 
 A random plasma glucose of 200 mg/dl (11.1 mmol/L) or higher in a patient 
with classic symptoms of hyperglycaemia (i.e., polyuria, polydipsia, 
polyphagia, weight loss) or hyperglycaemic crisis 
 
Normal Glucose Homeostasis: 
 Plasma glucose is maintained at a rather consistent value of approximately 
90 mg/dl (5 mmol/l), with a maximal increase of not exceeding 165 mg/dl (9.2 
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mmol/l) after a meal24 or a decrease down to not lower than 55 mg/dl (3.1 mmol/l) 
after exercise or a moderate 60-hour fast. Glucose can be from dietary source or is 
either from the gluconeogenesis in liver and kidney or the breakdown of glycogen 
(glycogenolysis) in liver. This glucose may be stored directly as glycogen through 
the process of glycogenesis in liver or may undergo glycolysis, which can be non-
oxidative, producing pyruvate or oxidative, through oxidization of acetyl CoA to 
carbon dioxide and water in the tricarboxylic acid cycle or commonly known as 
Krebs cycle (Figure 1)25.  
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Figure 1. Fate of Glucose25 
 
Glucose Homeostasis Regulators: 
Insulin  
This major regulator affects glucose metabolism both directly and 
indirectly. Its receptors are available in insulin-sensitive organs such as liver, 
kidney, muscle and adipose tissue. Activation of insulin signalling upon binding of 
insulin to insulin receptors causes suppression of gluconeogenesis in liver and 
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kidney26, translocation of glucose transporter-4 (GLUT 4) from inner membranes 
to plasma membrane in liver, muscles and adipose tissue to increase glucose 
uptake27, and inhibition of free fatty acid release into circulation28. As free fatty 
cid stimulates gluconeogenesis and reduce glucose transport into cells, release of 
insulin also indirectly regulates gluconeogenesis and glucose transport through 
free fatty acids. Besides, insulin promotes glycogen synthesis by inhibiting 
glucose-6-phosphatase (G6Pase) and glycogen phosphorylase while stimulating 
glycogen synthase29. Increased plasma glucose results in increase in plasma insulin 
while decrease in plasma glucose causes reduction in plasma insulin level as well.  
Glucagon  
Unlike insulin secreted from pancreatic β cells, glucagon is secreted from 
α-cells of the pancreas. Glucagon secretion is stimulated by hypoglycaemia 
whereas hyperglycaemia will inhibit its secretion. Glucagon acts exclusively on 
liver by activating glycogen phosphorylase and results in immediate glucose 
release. Further action of glucagon will be through stimulation of 
gluconeogenesis30.  
Catecholamines 
Catecholamines are molecules that act as both hormone in blood circulation 
and neuromodulator in central nervous system. During stress and hypoglycaemia, 
catecholamine are released and they inhibit insulin secretion and action. In the 
liver, through β2-adrenergic receptors, they activate glycogen phosphorylase and 
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augment gluconegenesis24. In the kidney, they are potent stimulators of 
gluconeogenesis. In skeletal muscle, they reduce glucose uptake and stimulate 
glycogenolysis. They also activate lipase and result in lipolysis in adipose tissue to 
increase release of free fatty acid31.  
Growth Hormone and Cortisol  
Both metabolic actions of growth hormone and cortisol are antagonistic to 
those of insulin. They increase secretion of gluconeogenic enzymes, reduce 
glucose transport and inhibit lipolysis. In addition, cortisol also impairs insulin 
secretion and therefore further debilitating insulin signalling.  
Free Fatty Acids  
As mentioned before, increased plasma free fatty acids will result in 
stimulation of renal and hepatic gluconeogenesis, inhibition of glucose transport in 
muscles and adipose tissue and competition with glucose as metabolic fuel32.  
 
Incretins 
Incretins are hormones secreted by intestine in response to nutrients 
ingestion. Their main effect is to stimulate pancreas to release insulin after meals 
intake. Two incretin hormones were identified so far: gastric inhibitory 
polypeptide (GIP) and glucagon-like peptide-1 (GLP1). Both of them have short 
half-life due to rapid digestion by proteolytic enzyme known as dipeptidyl 
peptidase-4 (DPP-4).  
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Pathogenesis of IDDM 
Type 1 diabetes mellitus is characterized by autoimmune destruction of 
insulin-producing β-cells in pancreas by alteration of CD4+ and CD8+ T cells and 
macrophages which causes infiltration in the islets of langerhans. 33 
 
Pathogenesis of NIDDM  
Although NIDDM makes up most cases of diabetes mellitus, its 
pathogenesis remains unclear, most probably due to its heterogeneity. Two main 
factors account for the development of NIDDM, which are the genetic factors and 
the environmental influences. Studies have shown that most patients have a 
positive family history and the risk for developing NIDDM is increased up to 40% 
by having a first-degree relative with the disease34. Environmental factors such as 
physical inactivity, obesity and dietary habits may interact with genetic factors and 
increase the risk of developing diabetes.  
β-cell dysfunction: 
Compared to normoglycaemic subjects, impaired glucose tolerance (IGT) 
subjects secrete less insulin at any given glucose level35. Islet β-cells function 
declines progressively from IGT to complete glucose intolerance (CGI) which 
appears to be the reason why patients who are initially well controlled by a single 
oral hypoglycaemic agent require increasing dose or combined agents to maintain 
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glycaemic indices36. There are several possible causes that result in β-cells 
dysfunction. Glucotoxicity and lipotoxicity are conditions where islet β-cells are 
exposed to high glucose or free fatty acids levels chronically. Long-term exposure 
to high glucose and free fatty acid levels impair insulin secretion from β-cells37. 
Human islet amyloid polypeptide (IAPP) or amylin, is normally co-localized 
within the same secretory vesicles as insulin and co-released with insulin in 
response to glucose or non-glucose secretagogues38. Decreased IAPP release but 
increased islet amyloid deposit has always been found in NIDDM39 and amyloid 
deposition has been proposed to decrease β-cell mass40.  
Insulin Resistance: 
Instead of impaired insulin secretion, in some NIDDM patients, 
hyperinsulinemia coexists with hyperglycaemia, which is commonly associated 
with obesity and insulin resistance41. By using hyperinsulinemic-euglycemic 
clamp technique, obese and diabetic patients have been correlated to decreased 
responsiveness or diminished sensitivity in insulin-stimulated whole-body glucose 
disposal42. Reduced numbers of insulin receptors, impairments in insulin receptor 
substrate and PI3K are primarily related to insulin resistance. Besides genetic 
factor, acquired insulin resistance gains much attention for the prevention and 
progression of the disease. Owing to dyslipidaemia in obese patients, elevated free 
fatty acid levels are associated with non-alcoholic hepatic steatosis, insulin 
resistance, decrease in skeletal muscle glucose disposal and increased hepatic 
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glucose production43. Apart from decreasing β-cell function, chronic physiological 
increment in the plasma glucose concentration also leads to progressive insulin 
resistance in NIDDM44. However, to date, it is still unclear with regard to the 
relative contributions of pancreatic β-cell dysfunction and insulin resistance to the 
pathogenesis of NIDDM.  
 
Complications of diabetes mellitus: 
Diabetes predisposes patients to opportunistic infections, vascular and 
neurological complications. Based on its pathophysiology diabetes mellitus can be 
acute or chronic. 
 Acute complications 
These include diabetic ketoacidosis (DKA) and non-ketotic hyper-osmolar 
state (NKHS). Diabetic ketoacidosis is seen primarily in individuals with type 1 
diabetes mellitus while non-ketotic hyperosmolar state is prevalent in individuals 
with type 2 diabetes mellitus. The two disorders are associated with absolute or 
relative insulin deficiency, volume depletion and altered mental state45. In DKA, 
insulin deficiency is combined with counter-regulatory hormone excess with 
respect to glucagon, catecholamines, cortisol and growth hormone46. The 
decreased ratio of insulin to glucagon promotes gluconeogenesis, glycogenolysis 
and ketone body formation in the liver and also increases free fatty acid and 
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amino-acid delivery from fat and muscle to the liver47. Ketosis results from a 
marked increase in free fatty acid release from adipocytes due to increased 
lipolysis48. In DKA, nausea and vomiting are often present. Severe DKA may 
result in lethargy and central nervous system depression eventually leading into 
coma. Cerebral edema, an extremely serious complication, is seen most frequently 
in children49. 
Non-ketotic hyper-osmolar state is most commonly seen in elderly 
individuals with type 2 diabetes mellitus. Its most prominent features include 
polyuria, postural hypotension, and a variety of neurological symptoms including 
altered mental state, lethargy, seizure and possibly coma. Insulin deficiency and 
inadequate fluid intake are the underlying causes of NKHS. Hyperglycaemia 
consequent to insulin deficiency induces an osmotic diuresis leading to excessive 
intravascular volume depletion50. 
 
Chronic complications: 
The chronic complications of diabetes mellitus affect multiple organs and 
are responsible for the morbidity and mortality associated with the disease. 
Chronic complications can be either vascular or nonvascular. Vascular 
complications are then subdivided into micro vascular (retinopathy, neuropathy 
and nephropathy) and macro vascular complications (coronary artery disease, 
peripheral vascular disease and cerebrovascular disease) 51. Nonvascular 
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complications include gastroparesis, sexual dysfunction and skin changes. 
Diabetes mellitus is the most common cause of adult blindness, a variety of 
debilitating neuropathies, cardiac and cerebrovascular disorders52. 
Early in the course of diabetes, intracellular hyperglycaemia causes 
abnormalities in blood flow and increased vascular permeability. This reflects 
decreased activity of vasodilators such as nitric oxide, increased activity of 
vasoconstrictors such as angiotensin II and endothelin-1 and production of 
permeability factors such as vascular endothelial growth factor. In diabetes, 
arterial endothelial dysfunction seems to involve both insulin resistance specific to 
the phosphatidylinositol–3-OH kinase pathway and hyperglycaemia53. 
Diabetic retinopathy 
Diabetic retinopathy occurs in 75% of all persons having diabetes for more 
than 15 years and is the most common cause of blindness. The risk of developing 
diabetic retinopathy or other micro vascular complications of diabetes depends on 
the duration and severity of hyperglycemia54. Diabetic retinopathy is classified 
into two stages, non-proliferative and proliferative. The non-proliferative stage 
appears late in the first decade or early in the second decade of disease and is 
marked by retinal vascular micro aneurysms, small haemorrhages in the middle 
layers of the retina, and cotton-wool spots and includes loss of retinal pericyte, 
retinal edema resulting from increased retinal vascular permeability, alterations in 
regional blood flow, and abnormal retinal microvasculature, all of which lead to 
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retinal ischemia55. Proliferative retinopathy is characterized by the formation of 
new blood vessels on the surface of the retina in response to retinal hypoxia. The 
newly formed vessels may appear at the optic nerve and/or macula and rupture 
easily, leading to vitreous haemorrhage, fibrosis and retinal detachment resulting 
in blindness56. 
Diabetic Neuropathy 
The precise nature of injury to the peripheral nerves from hyperglycaemia 
is not known but likely related to mechanisms such as polyol accumulation, injury 
from advanced glycosylated end products and oxidative stress. Peripheral 
neuropathy in diabetes may manifest in several different forms, including sensory, 
focal/multifocal and autonomic neuropathies. About half of all people with 
diabetes have some degree of neuropathy, which can be polyneuropathy, mono-
neuropathy and/or autonomic neuropathy57. Polyneuropathy is the most common 
form of neuropathy in diabetes. There is loss of peripheral sensation which, when 
coupled with impaired micro vascular and macro vascular junction in the 
periphery, can contribute to non-healing ulcers, the leading cause of non-traumatic 
amputation58. There is thickening of axons, decrease in microfilaments, and 
capillary narrowing involving small myelinated or non-myelinated C-fibres. It can 
occur both from direct hyperglycaemia-induced damage to the nerve parenchyma 
and from neuronal ischemia leading to abnormalities of micro vessels, such as 
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endothelial cell activation, pericyte degeneration, basement membrane thickening 
and monocyte adhesion59. 
Pure sensory neuropathy is relatively rare and associated with periods of 
poor glycaemic control or considerable fluctuation in diabetes control. It is 
characterized by isolated sensory findings without signs of motor neuropathy. 
Symptoms are typically most prominent at night. Mono-neuropathy is less 
common than polyneuropathy and includes dysfunction of isolated cranial or 
peripheral nerves. Autonomic neuropathy can involve multiple systems, including 
cardiovascular, gastrointestinal, genitourinary, sudomotor and metabolic 
systems60. 
Diabetic Nephropathy 
Diabetic nephropathy is defined by proteinuria greater than 500 mg in 24 
hours, but this is preceded by lower degrees of proteinuria, or “micro 
albuminuria.” Micro albuminuria is defined as albumin excretion of 30–299 mg 
per 24 hours61. Without intervention, diabetic patients with micro albuminuria 
typically progress to proteinuria with decreased glomerular filtration rate and end 
stage renal failure62. This progression occurs in both type 1 and type 2 diabetes. 
Dysfunction of the glomerular filtration is attributed to changes in synthesis and 
catabolism of various glomerular basement membrane macromolecules such as 
collagen and proteoglycans, leading to an increase in glomerular basement 
thickening63. Another possible mechanism to explain the increase in permeability 
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of the glomerulus is the increase in renal vascular endothelial growth factor 
(VEGF) levels observed in preclinical models of diabetes, since VEGF is both an 
angiogenic and a permeability factor64. 
Cardiovascular disorders 
In diabetes mellitus there is marked increase in several cardiovascular 
diseases, including peripheral vascular disease, congestive heart failure, coronary 
artery disease, myocardial infarction. Cardiovascular disease is the primary cause 
of death in people with either type 1 or type 2 diabetes65. 
Macro vascular complications may be unaffected or even worsened by 
diabetic therapies. An improvement in the lipid profiles of individuals in the 
intensive group (lower total and low-density lipoprotein cholesterol, lower 
triglycerides) suggested that intensive therapy may reduce the risk of 
cardiovascular mortality. In addition to coronary artery disease, cerebrovascular 
disease is increased in individuals with diabetes mellitus66. Individuals with 
diabetes mellitus have increased incidence of congestive heart failure the aetiology 
of which may include factors such as myocardial ischemia from atherosclerosis, 
hypertension and myocardial cell dysfunction secondary to chronic 
hyperglycaemia. Low density lipoprotein particles found in type 2 diabetes are 
more atherogenic and are more easily glycated and susceptible to oxidation67. 
Hypertension 
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Hypertension is up to twice as common in patients with diabetes as in the 
general population. The central pathological mechanism in macro vascular disease 
is the process of atherosclerosis, which leads to narrowing of arterial walls 
throughout the body. Atherosclerosis is thought to result from chronic 
inflammation and injury to the arterial wall in the peripheral or coronary vascular 
system68. In response to endothelial injury and inflammation, oxidized lipids from 
low density lipoprotein particles accumulate in the endothelial wall of arteries. 
This results in the loss of elastic tissue from the walls of the medium and large 
arteries, which consequently become rigid. When elastic tissue is lost the arteries 
become increasingly less able to absorb the pressure wave, which is pumped into 
the circulation with every pulse, the pressure within the system therefore rises and 
the blood pressure goes up. High blood pressure in diabetes appears to hasten the 
slide to kidney failure; it accelerates the process of atherosclerosis, and is also 
associated with an increased mortality from stroke and Myocardial Infarction69. 
 
 
Infections 
Individuals with diabetes mellitus exhibit a greater frequency and severity 
of infection70. The reasons for this include incompletely defined abnormalities in 
cell-mediated immunity and phagocyte function associated with hyperglycaemia 
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as well as diminished vascularization secondary to long-standing diabetes71. Many 
common infections are more frequent and severe in the diabetic population, 
whereas several rare infections are seen almost exclusively in the diabetic 
population. These include rhino-cerebral mucormycosis and malignant otitis 
externa, which is usually secondary to Pseudomonas aeruginosa infection in the 
soft tissue surrounding the external auditory canal72. Pneumonia, urinary tract 
infection, skin and soft tissue infections are all more common in the diabetic 
patients. The most common organisms causing infections in diabetic patients are 
Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae and 
Mycobacterium tuberculosis73. Diabetic patients have an increased rate of 
colonization of S. aureus in skin folds, nares and also have a greater risk of 
postoperative wound infections. 
 
Management of NIDDM and IDDM 
 Management of diabetes and maintaining near-normal plasma glucose 
levels are of utmost importance in order to prevent the development of diabetic 
complications such as nephropathy, neuropathy, retinopathy, dyslipidaemia and 
cardiovascular diseases, which are comparatively more lethal. A number of 
therapeutic choices are available for the management of the disease; however, 
none are free of disadvantages. Pharmacological intervention remains the most 
effective way to control plasma glucose level but it is always associated with 
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unwanted side effects. Sulfonylureas initiate insulin release even when glucose 
level is low74 and therefore are more likely to cause hypoglycemia75. Besides, as 
sulfonylureas stimulate insulin secretion, their effective use requires significant 
residual β-cell function76. Efficacy is better in patients shortly after diagnosis of 
NIDDM when most β-cell function is still preserved77. Thiazolidinedione’s often 
cause weight gain which will further deteriorate insulin resistance and increase 
cardiovascular mortality risk e.g. pioglitazone78. The use of biguanides, such as 
metformin, is always associated with acidosis and severe gastrointestinal upset79. 
Over the past 30 to 40 years, studies using approaches ranging from 
epidemiological to interventional and molecular technologies have proven that 
regular exercise is effective in preventing and delaying metabolic diseases and its 
complications80. Unfortunately, sustained benefits are difficult to achieve due to 
incapability of human nature to adhere to exercise regimen. Also, evolutionarily 
humans have been driven to minimize energy expenditure and remain sedentary. 
As a result, dietary approach remains a crucial tool to achieve the goal of cost-
effective management with minimal complications but maximal quality of life. 
Before the introduction of the therapeutic use of insulin, diet is the main form of 
treatment of the disease, and dietary measures included the use of traditional 
medicines which are mainly derived from plants81. Even now, approximately 80% 
of the third-world population is still dependent on traditional medicines. 
Metformin, the most prescribed and first-choice agent in NIDDM 
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pharmacotherapy, was derived from Galega officinalis (also known as Goat’s rue 
or French lilac), a herb known for relieving symptoms of diabetes since the Middle 
Ages82.  
 In addition, in recent years, a wealth of evidence has been obtained, 
correlating lower consumption of carbohydrate, saturated fat, processed food and 
higher consumption of fruits, vegetables, legumes, coffee, and tea with lower risk 
of diabetes and improved glucose and lipid metabolism. It is evident that plant-
based foods are rich in phytochemicals known as polyphenols which include 
flavonoids, phenolic acids, lignans and stilbenes, which have been shown to 
improve glucose homeostasis at several organ sites, including the (1) 
gastrointestinal tract, which regulates carbohydrate digestion and glucose 
absorption, (2) endocrine pancreatic system, which secretes key regulatory 
hormones, insulin and glucagon, in response to abnormal glucose levels, (3) liver, 
where glucose synthesis, glycogen storage and breakdown are initiated, (4) 
insulin-sensitive peripheral tissues like skeletal muscle and adipose tissue, where 
glucose is metabolized for energy or stored for future use. Drugs used in the 
treatment of diabetes mellitus is given below (Figure 2)20. 
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Figure 2. Drugs used in Diabetes Mellitus 
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Herbal medicines in the treatment of Diabetes Mellitus 
Herbal medicine is the oldest form of healthcare known to mankind. It was 
an integral part of the development of modern civilization. Fossil records reveal 
the human use of plants as medicines at least to the Middle Paleolithic age some 
60,000 years ago which was evidenced by a burial site of a Neanderthal man 
uncovered in 196083. Primitive man observed and appreciated the great diversity 
of plants available to him. Gradually, each tribe added the medicinal power of 
herbs in their area to its knowledge base. All cultures have long folk medicine 
histories that include the use of numerous plants. 
 The revival of interest in herbal medicines is firstly due to increased 
awareness of the limited horizon of synthetic pharmaceutical products to control 
major diseases and secondly due to the current widespread belief that 'green 
medicine' is safe and more accessible and affordable84 than the costly synthetic 
drug many of which have adverse side effects. The past decade has witnessed a 
tremendous resurgence in the interest and use of medicinal plant products 
especially from developed countries. According to a WHO estimate, about 80% of 
the world population relies on traditional systems of medicines for primary health 
care, where plants form the dominant component over other natural resources85. 
 In modern medicine no satisfactory effective therapy is still available to 
cure diabetes mellitus. There is increasing demand by patients to use natural 
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products with anti-diabetic activity due to side effects associated with the use of 
insulin and oral hypoglycemic agents. Recent overwhelming attention to plant 
products and alternative medicine has encouraged plant chemists, 
pharmacologists, biochemists and molecular biologists to combine their efforts in 
a search for natural agents that can limit diabetes mellitus and its complications. 
 
Animal models in diabetes: 
1. Chemical induced Diabetes 
1.1. Alloxan induced diabetes 
 Alloxan is most prominent chemical compound used in diabetogenic 
research. In research it is used for induction of Type 1 diabetes. Alloxan is a urea 
derivative which causes selective necrosis of the β- cells of pancreatic islets. It has 
been widely used to induce experimental diabetes in animals such as rabbits, rats, 
mice and dogs with different grades of disease severity by varying the dose of 
alloxan used86. 
1.2. Streptozotocin (STZ) induced diabetes 
 Streptozotocin is a monofunctional nitrosourea derivative. First isolated 
from Streptomyces achromogenes87. It has been used alone or in combination with 
other chemotherapeutic drugs (vincristine, 5-fluorouracil, methyl-CCNU, 
procarbazine and 6-thioguanine) for the treatment of colorectal carcinomas and 
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other gastrointestinal cancers, but severe toxicity and myelosuppression were 
observed in most of the patients.  
  In the bacterial cells; it renders special reaction with cytosine groups, 
resulting in degeneration and destruction of DNA. The streptozotocin enters the 
pancreatic cell via a glucose transporter-GLUT2 causing DNA alkylation which 
further induces activation of poly ADP ribosylation and releases nitric oxide. This 
results in destruction of pancreatic β -cells leading to insulin dependent diabetes88. 
1.3. Dithizone induced diabetes: 
 Chemical name of dithizone is 8-(p- toluene- sulfonyl amino)–quinoline (8- 
TSQ).  Dithizone is an organosulfur compound that acts as a chelating agent and 
forms complexes with lead, zinc and mercury. Zinc-chelating agent such as 
dithizone causes diabetes in laboratory animals. Dithizone has abilities to 
permeate membranes and to complex zinc inside liposomes with the release of 
protons, that can enhance diabetogenicity. When such complexing agents are 
added to lipid vesicles at pH 6 containing entrapped zinc ions, they acidify the 
contents of these vesicles. Such proton release occurs within the zinc-containing 
insulin storage granules of pancreatic beta-cells; solubilization of insulin would be 
induced which leads to osmotic stress and eventually the granule rupture and 
finally diabetes is induced89. 
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1.4. Gold thioglucose induced diabetes: 
 Gold thioglucose is diabetogenic compound, which induces polyphagia and 
severe obesity induced Type -2 diabetes. It is derivative of sugar glucose. Gold 
thioglucose is precipitated with methanol and recrystallized with water and 
methanol. Gold thioglucose developed obesity induces diabetes in genetically 
normal mouse strains. Gold thioglucose treated DBA/2 (Dilute Brown Non- 
Agouti), C57BLKs, and BDF1 mice gained weight rapidly and significantly 
increase random plasma glucose level within 8-12 weeks. These mice showed 
impaired insulin secretion, mainly in early phase after glucose load and reduced 
insulin content in pancreatic islets90.  
1.5. Monosodium glutamate induced diabetes: 
 It is most abundant naturally occurring non- essential amino acid and freely 
soluble in water. Monosodium glutamate causes a very large insulin response after 
ingestion. It is developed glycosuria in both male and female mice but not induced 
polyphagia. Within 29 weeks level of glucose concentration in blood, total 
cholesterol and triglyceride were higher91.  
2. Virus Induced Diabetes  
 Juvenile- onset diabetes mellitus may be due to virus infections and beta- 
cell specific autoimmunity. In 1960s Gamble and co – workers reported newly 
diagnosed juvenile- onset diabetes (Type- 1) due to viral infections. At present 
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time two viruses are reported first is D- variant of encephalomyocarditis (EMC-D) 
and another is Coxsackie virus92.  
2.1. D- Variant Encephalomyocarditis 
 EMC- D virus can infect and destroy pancreatic beta cells in certain inbred 
strains of mice and produce insulin dependent hyperglycemia. Pre-treatment with 
a potent immunosuppressive drug, cyclosporine-A increases severity and 
incidence of diabetes in ICR Swiss mice. In 1992 Utsugi et al demonstrated the 
clone of EMC-D virus known as NDK25. Intraperitoneal injection of NDK25 
develops non- insulin dependent diabetes mellitus93.  
2.2. Coxsackie Viruses  
 Coxsackie viruses are also a possible cause of diabetes in mice; it can infect 
and destroy pancreatic acinar cells while leaving the adjacent islets of langerhans 
intact. Coxsackie B4 virus is strongly associated with the development of insulin-
dependent diabetes mellitus in humans. Diabetes induced by Coxsackie virus 
infection is a direct result of local infection leading to inflammation, tissue 
damage, and the release of sequestered islet antigen resulting in the restimulation 
of resting auto reactive T cells, further indicating that the islet antigen sensitization 
is an indirect consequence of the viral infection94.  
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3. Hormone Induced Diabetes  
3.1. Growth hormone induced diabetes  
 Growth hormone has long distinguished history in diabetes, with possible 
participation in the development of renal complications. Repeated administration 
of growth hormone in cats and adult dogs induces diabetes with all symptoms of 
diabetes including severe ketonuria and ketonemia. More prolonged 
administration of growth hormone produced permanent diabetes, there was loss of 
pancreatic islets tissues and of beta cells and only traces of insulin could be 
extracted from pancreas95.  
3.2. Corticosteroid induced diabetes  
 Corticosteroid used to reduce inflammation can lead to diabetes, which is 
called steroid diabetes. The most common glucocorticoids which causes steroid 
diabetes are prednisolone and dexamethasone. Glucocorticoids oppose insulin 
action and stimulate gluconeogenesis, especially in the liver, resulting in a net 
increase in hepatic glucose output and induce insulin resistance, hyperglycemia, 
and hyperlipidemia96. 
4. Genetically Induced Diabetes 
 The AKITA mouse was derived in Akita, Japan from a C57BL/6NSlc 
mouse with a spontaneous mutation in the insulin 2 gene preventing correct 
processing of pro-insulin. This causes an overload of misfolded proteins and 
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subsequent ER stress. This results in a severe insulin-dependent diabetes starting 
from 3 to 4 weeks of age, which is characterized by hyperglycaemia, 
hypoinsulinaemia, polyuria and polydipsia. Untreated homozygotes rarely survive 
longer than 12 weeks. The lack of beta cell mass in this model makes it an 
alternative to streptozotocin-treated mice in transplantation studies. It has also 
been used as a model of type 1 diabetic macro vascular disease and neuropathy88. 
In addition, this model is commonly used to study potential alleviators of ER 
stress in the islets and in this respect models some of the pathology of type 2 
diabetes. 
STZ – Nicotinamide induced diabetes – Emerging model 
 Administration of both Streptozotocin (STZ) and Nicotinamide (NA) has 
been proposed to induce experimental diabetes in the rat. STZ is well known to 
cause pancreatic β-cell damage, whereas NA is administered to rats to partially 
protect insulin-secreting cells against STZ. STZ is transported into β-cells via the 
glucose transporter GLUT2 and causes DNA damage leading to increased activity 
of poly ADP-ribose polymerase (PARP-1). However, exaggerated activity of this 
enzyme results in depletion of intracellular NAD+ and ATP, and the insulin-
secreting cells undergo necrosis. The protective action of NA is due to the 
inhibition of PARP-1 activity. NA inhibits this enzyme, preventing depletion of 
NAD+ and ATP in cells exposed to STZ. Moreover, NA serves as a precursor of 
NAD+ and thereby additionally increases intracellular NAD+ levels. The severity 
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of diabetes in experimental rats strongly depends on the doses of STZ and NA 
given to these animals. Therefore, in diabetic rats, blood glucose may be changed 
in a broad range from slight hyperglycaemia to substantial hyperglycaemia 
compared with control animals. Similarly, blood insulin may be slightly decreased 
or substantial hypoinsulinemia may be induced. In vitro studies demonstrated that 
the insulin-secretory response to glucose is attenuated in STZ-NA induced diabetic 
rats compared with control animals. This is due to reduced β -cell mass as well as 
metabolic defects in the insulin-secreting cells. Results of numerous experiments 
have demonstrated that this model of diabetes is useful in studies of different 
aspects of diabetes97. 
Plant Profile 
Botanical name of the plant is Tephrosia purpurea which belongs to the 
family Leguminosae (Fabaceae). Common name of the plant is Wild Indigo, 
Saraphunkha. In Tamil it is called as ககொள்ளுக்கொவேலை. Tephrosia purpurea is 
a self-generating erect or spreading perennial herb found throughout India. It can 
be found as an ingredient in traditional herbal formulations.  
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Figure 3. Tephrosia purpurea (Linn) Pers. 
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Tephrosia purpurea is a small shrub that grows up to 1.5 meters tall. It has 
bi-pinnate leaves with 7 to 15 leaflets, the terminal leaflet being solitary.  
Geographical Distribution 
 Tephrosia purpurea occurs naturally in grassy fields, waste places and 
thickets, on ridges and along roadsides, in Java. In Hawaii, it grows near the 
seashore. Tephrosia purpurea is native to tropical Asia, and is found from India 
and Sri Lanka to southern China and through South-East Asia to tropical Australia 
and the Polynesian Islands. It is now naturalized and cultivated pan tropically. 
Tephrosia purpurea grow at an altitude up to 400 m altitude, it generally grows at 
low altitudes but may be found to 1300 m altitude. It prefers dry, gravelly or rocky 
and sandy soils, but in India it grows well on loamy soils98. 
 
Ethno botanical uses of Tephrosia purpurea 
 The plant has thermogenic, anti-helminthic, digestive, laxative, diuretic, 
uterine tonic, anti-inflammatory and antipyretic property  
 The roots are useful in various infectious and inflammatory skin diseases. 
Some of its well - known use are in acne, boils, Asthma.  
 The leaves are useful in gastrointestinal and genitourinary disorders. 
 The seeds are also useful in skin diseases.99 
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Uses as folk medicine 
 Tephrosia purpurea was widely used as folklore medicine in most of the 
countries. Commonly it is used for cough, Chest tightness, bilious febrile attacks, 
and obstructions of spleen, liver and kidney. The leaves of Tephrosia purpurea 
was used to purify the blood, and used to cure for boils and pimples. Roots of 
Tephrosia purpurea was used for dyspepsia and chronic diarrhoea by the 
traditional healers. Infusion of seeds used as cooling medicine and decoction of 
pounded leaves used for snake bites.  
 In Ceylon, Tephrosia purpurea roots are used as anti-helminthic for 
children. Decoction of roots used as nematocide for treatment of Toxocaracanis 
larvae which causes lung disease.  The plant is also used for colic, diarrhoea and 
dyspepsia. Fresh root-bark, ground and made into a pill, mixed with a little black 
pepper, used for obstinate colic. 
 In Indian medicine,   Tephrosia purpurea is one of the common ingredients 
of various formulations which are used in the treatment of bilious febrile attacks, 
liver and splenic affections, cirrhosis and hepatitis.  The oil obtained from the 
seeds of Tephrosia purpurea was applied topically to cure scabies, eczematous 
itching, and other skin eruptions. The plant was used to treat piles, syphilis and 
gonorrhoea by the local healers.  In Punjab, infusion of seeds considered cooling 
agent. In some part of India, the plant seed was used as a substitute for coffee and 
as insect repellent100. 
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Phytochemical review of Tephrosia purpurea: 
 Chaudhari et al., 2012, demonstrated regarding the presence of glycosides, 
various phytochemical constituents especially flavonoids in Tephrosia 
purpurea101.  
 Chang et al., 2000, isolated three novel flavonoids, (+)-tephrorins A and B 
and (+)-tephrosone, from Tephrosia purpurea leaves extract102.  
  Venkata Rao and RangaRaju, 1984, isolated a flavanone, named as 
purpurin and identified as 2, 3 dihydrosemiglabrin from the seeds of 
Tephrosia purpurea103. 
  Gupta et al., 1980, isolated and characterized ten unusual and closely 
related flavonoids from the roots of Tephrosia purpurea104.  
 
Studies in accordance with our study: 
 Pavana et al, 2007, demonstrated the anti-hyperglycemic activity of 
aqueous extract of Tephrosia purpurea seeds in streptozotocin induced 
diabetic rats. Profound alterations in the concentrations of blood glucose, 
lipids and lipoproteins were observed in diabetic rats105.  
 Hutchings and Van Staden, 2012, evaluated the ethanolic extract of plant 
Tephrosia purpurea shows anti-hyperglycemic activity against high fat diet 
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Wistar rat’s model. A decrease in total cholesterol level of rats compared to 
hyperlipidemic control was observed106. 
 Pavana et al., 2009, studied and stated that, aqueous seed extract of 
Tephrosia purpurea has potent anti-hyperglycemic and antioxidant effects 
in Streptozotocin-induced diabetic rats107.  
 Pavana et al., 2007, demonstrated that Tephrosia purpurea leaf extract has 
prominent anti-hyperglycemic and anti-hyperlipidemic effects in 
Streptozotocin induced diabetic rats108. 
 Sayad Mustak, 2012, made a comparative study of Tephrosia purpurea 
(Linn) leaves and Lovastatin on cholesterol level of hyperlipidemic Wistar 
rats and it was found to be significant decrease in total cholesterol level of 
rats when compared to hyperlipidemic control which was equipotent as that 
of Lovastatin109.  
 Sangeetha and Krishnakumari, 2010, documented the hepatoprotective role 
of ethanolic extract of the root of Tephrosia purpurea against CCl4 induced 
oxidative damage in the liver of rats110.  
 Khatria et al., 2009, reported the hepatoprotective activity of aqueous–
ethanolic extract of Tephrosia purpurea aerial parts (100, 300 and 500 
mg/kg/day) against thioacetamide induced hepatotoxicity in Wistar rats111. 
There are several studies proved the various properties of different 
parts of Tephrosia purpurea such as anti-hyperglycemic, hepatoprotective 
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and lipid peroxidative effects. But none available on the whole plant extract 
of Tephrosia purpurea for anti-hyperglycemic activity and there are also no 
studies available on the Reno protective effect of Tephrosia purpurea. 
Other studies related to Pharmacological activities of Tephrosia Purpurea: 
 
 Rajaram et al., 2015, report that the roots of Tephrosia purpurea showed 
neuroprotective activity against haloperidol induced Parkinson’s disease in 
rats78.  
 Manjula et al., 2013, documented the anthelmintic activity of aqueous and 
methanolic leaf extract of Tephrosia purpurea using Pheretima posthuma 
and the results showed that the anthelmintic activity was comparable to the 
standard Albendazole112. 
 Ashok Kumar et al., 2012, explored the diuretic potential of Tephrosia 
purpurea plant extract on Wistar rats113. 
 Gopalakrishnan et al., 2010, evaluated the anti-inflammatory and analgesic 
activity of ethanolic extract of Tephrosia purpurea aerial and root, which 
showed dose dependent activity against both acute and chronic models114.  
 Rumit Shah et al., 2010, reported the hydro alcoholic extract of Tephrosia 
purpurea showed antioxidant activity by inhibiting DPPH and hydroxyl 
radical, nitric oxide and super oxide anion scavenging, hydrogen peroxide 
scavenging, and reducing power activities115. 
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 Damre et al., 2003, reported the cellular and humoral immunomodulatory 
activity of the flavonoid fraction of Tephrosia purpurea in-vivo116.  
 
Pharmacology of Glibenclamide – Standard drug 
 Glibenclamide is a potent second-generation sulfonylurea drug that 
improves glucose control by acting both on insulin secretion and on insulin action. 
The predominant effect of sulfonylureas was thought to be on insulin secretion, 
while the effect on insulin sensitivity may be mediated either through the 
improvement of metabolic control or via a direct peripheral effect117. The 
mechanism of action of glyburide seems to be initiated by the linkage of drug 
molecules with surface receptor in the β-cell surface and subsequent reduction of 
conductance of the ATP-sensitive K+ channels118. The reduced K+ efflux 
determines membrane depolarization and influx of Ca++ through Ca++ channels 
that eventually determine insulin secretion. In recent years increasing evidence has 
suggested a possible role of glibenclamide on insulin action at the level of 
different organ/tissues. Whether this drug effect is due to a direct, specific 
mechanism or is mediated by an improvement in glycemic control and 
consequently via a reduction of glucose-determined insulin resistance (glucose 
toxicity) is at present unknown. Finally, new interest in this class of drugs and in 
any other procedure that restores co-secretion of C-peptide and insulin (like whole 
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pancreas or islet of Langerhans transplantation) has been triggered by a number of 
recent reports showing a positive effect of C-peptide (at a chronic concentration as 
low as ~0.5 ng/ml) on the development of diabetic complications, this effect being 
mediated by activation of the Na+/K+ ATPase pump118. 
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5. MATERIALS AND METHODS 
 
MATERIALS AND METHODS 
Plant Materials 
Collection & Identification  
 The whole plant, Tephrosia purpurea Linn. was collected from the road 
side of Erode, Tamilnadu, during the month of October. It was authenticated by 
Prof.R.Duraisamy, Pharmacognosist and the voucher specimen 
(NCP/Phcog/2016/0202) has been retained, for future reference in the herbarium 
of Pharmacognosy department, Nandha College of Pharmacy, Erode, India. 
Extraction of Plant Material 
 The collected Tephrosia purpurea, was washed in running tap water to 
remove the soil debris, shade dried and grounded using mechanical blender to get 
coarse powder. The 200gm of coarsely powdered Tephrosia purpurea whole plant 
was soaked in one litre of ethanol (90%) in a tightly sealed flat bottom flask at 
room temperature, protected from sun light for 72 hrs with occasional shaking. 
After 72 hrs the mixture was filtered through muslin cloth and the solvent was 
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evaporated by rotary evaporator at 40oC to get dry mass. The dried ethanolic 
extract of Tephrosia purpurea was stored in desiccators and used for further 
pharmacological studies. 
 
Animals 
 Wistar albino rats of either sex weighing between 180 – 200 gms were used 
for this study. The animals were obtained from King’s Institute, Guindy and was 
housed in animal house, Karpaga Vinayaga Institute of Medical Sciences and 
Research Institute, Kancheepuram. On arrival, the animals were placed at random 
and allocated to treatment groups in polypropylene cages with paddy husk as 
bedding. Animals were housed at a temperature of 24±2oC and relative humidity 
of 30 – 70 %. A 12:12 light: day cycle was followed. All animals were allowed to 
free access to water and fed with standard commercial pelleted rat chaw (M/s. 
Hindustan Lever Ltd, Mumbai). All the experimental procedures and protocols 
used in this study were reviewed and approved by the Institutional Animal Ethics 
Committee (1818/GO/Ere/S/15/CPCSEA) and were in accordance with the 
Institutional ethical guidelines. 
Experimental Induction of Diabetes in Rats  
 Diabetes was induced experimentally in 12 hour fasted rats by a single 
intra-peritoneal injection of Streptozotocin (50mg/kg) dissolved in 0.1M of citrate 
buffer (pH 4.5), followed by intra peritoneal administration of Nicotinamide (120 
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mg/kg) after 15 minutes. Since STZ is capable of inducing fatal hypoglycaemia 
due to sudden marked release of insulin from the pancreas, the rats that had been 
administered STZ were provided after 6 hr with a 10% glucose solution orally for 
24 hr continuously so as to prevent hypoglycaemia. After 72 hr, rats with a blood 
glucose concentration above 200 mg/dl were considered to be diabetic and were 
used for further diabetic studies. 
Experimental Design 
 After the successful induction of experimental diabetes, the rats were 
divided into five groups each comprising a minimum of six rats (Table 1). 
 
Table 1 – Study animal groups  
Group I 
Normal rats received 0.1 % Carboxyl Methyl Cellulose Solution 
(1mg/kg) as vehicle through oral route. 
Group II 
Rats with STZ – Nicotinamide induced diabetic that were left 
untreated. 
Group III 
Rats with STZ – Nicotinamide induced diabetic that were treated for 
30 days with orally administered Glibenclamide (5mg/kg) 
Group IV 
Rats with STZ – Nicotinamide induced diabetic that were treated for 
30 days with orally administered ethanolic extract of   Tephrosia 
purpurea (200mg/kg). 
Group V Rats with STZ – Nicotinamide induced diabetic that were treated for 
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30 days with orally administered ethanolic extract of   Tephrosia 
purpurea (400mg/kg). 
 
Blood glucose levels were measured at different time intervals (0, 5th, 10th, 
15th and 30th day) during the study. At the end of experimental period, the rats 
were fasted overnight, anaesthetized with Pentobarbitone sodium and the blood 
was collected by retro-orbital puncture in non heparinized tubes. To obtain serum, 
blood samples were placed at room temperature for 30 minutes and centrifuged at 
3000 X g for 10 minutes and the supernatant were taken for the determination of 
Lipid profiles, Liver function (AST, ALT, and ALP) and Kidney function test. 
 
Determination of Blood Glucose 
1.) Glucometer was set out and a test strip, a sterile blade and an alcohol prep pad 
were arranged. 
2.) The rat tail was clean with alcohol to prevent infection. 
3.) Glucometer was turned and placed a test strip in the machine when the 
machine is ready. The indicator was observed to place the blood on strip. 
4.) The tip of the tail was cut with sterile blade to obtain a drop of blood.  
5.) The blood drop was placed on or at the side of the strip. 
6.) With in few seconds after placing the blood on strip, the blood glucose levels 
was displayed.  
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Blood glucose levels were measured at different intervals using one touch 
glucometer. 
 
 
Determination of Lipid Profile 
Total cholesterol  
 Total cholesterol in serum was determined by a colorimetric method. The 
assay principle is based on enzymatic hydrolysis and oxidation of cholesterol and 
the indicator compound, quinoneimine is formed from hydrogen peroxide and 4-
aminoantipyrine in the presence of phenol and peroxidase. The reagents consisted 
of 4-aminoantipyrine (0.03 mmol/l), phenol (6 mmol/l), peroxidase (≥0.5 U/ml), 
cholesterol esterase (> 0.15 U/ml), cholesterol oxidase (> 0.1 U/ml) and pipes 
buffer (80 mmol/L pH 6.8). The serum sample (10 μl) was mixed with 1 ml of 
reagent, incubated at 37oC for 5 min, and absorbance measured at 500 nm against 
the reagent blank119. The cholesterol standard was 5.17 mmol/l (200 mg/dl). The 
concentration of total cholesterol in the sample was calculated by  
 Total cholesterol = ΔAsample/ ΔAstandard x concentration of standard.  
 
Triglycerides 
 Serum triglycerides (TG) were determined by a colorimetric method. The 
assay principle is based on the enzymatic hydrolysis of TG with lipases and the 
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indicator is a quinoneimine formed from hydrogen-peroxide, 4-aminophenazone 
and 4-chlorophenol under the catalytic activity of peroxidase120. The enzyme 
reagent consisted of 4-aminophenazone (0.5 mmol/l), ATP (1.0 mmol/l), lipases 
(≥150 U/ml), glycerol-kinase (≥0.4 U/ml), glycerol-3-phosphate oxidase (≥1.5 
U/ml), peroxidase (≥0.5 u/ml). The serum sample (10 μl) was mixed with 1000 μl 
of enzyme reagent, incubated at 37oC for 5 min and absorbance measured at 500 
nm against the reagent blank. The TG standard was 200 mg/dl (2.29 mmol/l). The 
concentration of TG in the serum was calculated by  
 Total triacylglycerides =ΔAsample / ΔAstandard x concentration of 
standard.  
HDL Cholesterol 
 Serum HDL cholesterol was determined by a colorimetric method.  The 
assay principle is based on the following: the low density lipoproteins (LDL and 
VLDL) and chylomicron fraction is precipitated quantitatively by the addition of 
phophotungstic acid in the presence of magnesium ions. After centrifugation, the 
cholesterol concentration in the HDL fraction, which remains in the supernatant, is 
determined. The precipitation reagents consisted of phosphotungstic acid (0.55 
mmol/l) and magnesium chloride (25 mmol/l). The serum sample (200 μl) was 
mixed with 500 μl of precipitation reagent and centrifuged at 4000 rpm for 10 min. 
The supernatant (100 μl) was mixed with reagent (CH 200 1 ml), incubated at 
37oC for 5 min and absorbance measured at 500 nm against the reagent blank121. 
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The cholesterol standard was 200 mg/dl (5.17 mmol/l). The concentration of 
cholesterol in the supernatant was calculated by, HDL Cholesterol = ΔAsample / 
ΔAstandard x concentration of standard.  
 
 
 
LDL & VLDL Cholesterol 
 Low density lipoprotein (LDL) and Very low density lipoprotein (VLDL) 
were calculated according to Fried Wald formula122. 
 LDL = TC – HDL – VLDL  
 VLDL cholesterol = Triglycerides / 5.  
Determination of Liver Profile 
Estimation of AST and ALT 
Activities of serum Aspartate transaminase (AST) and Alanine 
transaminase (ALT) were assayed by the method of Reitman and Frankel, 1957123. 
0.2 ml of serum with 1 ml of substrate (aspartate and α-ketoglutarate for AST; 
alanine and α -ketoglutarate for ALT, in phosphate buffer pH 7.4) was incubated 
for an hour in case of AST and 30 minutes for ALT. 1 ml of DNPH solution was 
added to arrest the reaction and kept for 20 min in room temperature. After 
incubation 1 ml of 0.4N NaOH was added and absorbance was read at 540 nm. 
Activities expressed as IU/L. 
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Estimation of ALP  
  Three test-tubes were set up then into the 1st (test), added 5 ml of the 
substrate solution (p-nitro phenyl phosphate in glycine/NaOH buffer) followed by 
0.1 ml of serum124. After 30 minutes reaction at 370C, the optical density was 
measured at 405 nm. Into the 2nd tube, 5 ml of substrate solution was added with 
0.1 ml of serum. After mixing, the optical density was measured immediately. Into 
the 3rd tube, 0.1 ml of water was added with 5.0 ml of p – nitro phenol standard 
solution, optical density was measured.     
            OD of test – OD of blank           1000         1 
           IU/L =   -- -------------------------------- x -------- x --------x 10  
              OD of standard – OD of blank     0.1         30 
Determination of Renal Profile 
Estimation of Blood Urea  
 Labelled three test-tubes as B, T and S. into B, pipette, 0.02 ml water, into 
T, 0.02 ml blood and into S, 0.02 ml standard urea solution (40 mg urea in 100 ml 
of water). 0.1 ml of diacetylmonoxime solution and 5 ml of acid regent 
(Thiosemicarbazide) was added into all the test-tubes125. Mixed and kept in a 
boiling water bath for 15 minutes. After cooling, the absorbance was read at 540 
nm and concentration of urea in mg/dl was calculated.    
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Estimation of Serum Creatinine 
 Labelled three test-tubes as B, T and S. into B, pipetted, 2 ml of water, into 
T, 2 ml serum and 4 ml of water, into S, 3 ml of water and 1 ml of creatinine 
standard (4mg/dl). Then 2 ml of ammonium sulphate and 2 ml of sodium tungstate 
was added in all the three test-tubes. Centrifuged and removed 3 ml of supernatant 
from each test tube. To that 1 ml of picric acid and distilled water was added to the 
supernatant of test tubes B, T and S. Absorbance was read at 520 nm and 
concentration of serum creatinine in mg/dl was calculated126. 
Statistical Analysis 
 Results were represented as mean ± SEM. The data were analysed by using 
one way analysis of variance (ANOVA) followed by Dunnet’s‘t’ test using graph 
Pad version 3. P values < 0.05 were considered as significant. 
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6. RESULTS 
RESULTS 
Effect of Tephrosia purpurea on Blood Sugar Levels 
 The antidiabetic activity of ethanolic extract of Tephrosia purpurea plant 
was studied against the STZ – Nicotinamide induced diabetes in rats and the blood 
sugar levels of various time intervals were shown on table 2.  The blood sugar 
levels of diabetic control rats were higher than those of normal rats on 0, 5th, 10th, 
20th and 30th day. In diabetic rats, treated with 200 and 400 mg/kg of Tephrosia 
purpurea blood glucose level significantly lowered to 157.17±5.55 on 10th day 
(P<0.05) and to 189.00±5.05 on 5th day (P<0.01) respectively as compared to 
diabetic animals. The diabetic rats treated with reference control glibenclamide 
also significantly (P<0.001) lowered the blood sugar level to 184.50±3.89 on 5th 
day. On 15th day onwards until the end of the drug treatment, on 30th day 200 and 
400 mg/kg of Tephrosia purpurea and glibenclamide significantly (P<0.001) 
lowered the blood glucose as compared to diabetic control animals. 
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Table 2. Mean ± SEM on Blood Sugar Levels  
Values are in mean ± SEM (n=6), *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic Control 
 
 
Drug 
Treatment 
Mean Blood Sugar Level  (mg/dl) 
Before STZ 
+ 
Nicotinamide 
After STZ 
+ 
Nicotinamide 
0 Day 5th Day 10th Day 15th Day 30th Day 
Control 
1% CMC 
105.83± 
3.22 
98.00± 
3.91*** 
100.33± 
4.47*** 
101.17± 
4.67*** 
99.67± 
4.66*** 
97.17± 
3.03*** 
102.00± 
5.39*** 
Diabetic 
Control 
101.50± 
4.59 
213.00± 
4.07 
220.50± 
5.83 
228.83± 
3.17 
216.33± 
5.83 
226.50± 
2.57 
222.17± 
5.67 
Reference 
Control 
105.17± 
5.41 
212.00± 
4.56 
219.67± 
3.81 
184.50± 
3.89** 
143.17± 
2.73*** 
112.67± 
5.57*** 
103.33± 
5.34*** 
TP 200 
100.67± 
4.26 
211.33± 
4.49 
219.00± 
3.45 
210.00± 
4.07 
157.17± 
5.55* 
129.17± 
2.09*** 
114.17± 
3.28*** 
TP 400 
98.67± 
3.45 
208.83± 
6.09 
217.50± 
4.86 
189.00± 
5.05** 
150.83± 
6.04** 
119.67± 
4.36*** 
100.17± 
4.85*** 
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Figure 4. Effect of Ethanolic Extract of Tephrosia purpurea on Blood Sugar Levels 
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Effect of Tephrosia purpurea on Lipid Profile 
 The effect of ethanolic extract of Tephrosia purpurea on lipid parameters in 
STZ-nicotinamide induced diabetes in rats were shown in the Table. No. 3. In the 
animals of normal control the total cholesterol was 112.00±2.09 mg/dl, whereas 
the total cholesterol was enhanced in diabetic control rats up to 138.67±1.3 
3mg/dl. The 200 and 400mg/kg of ethanolic extract of Tephrosia purpurea 
significantly decreased the total cholesterol to 125.67±2.20 (P<0.05) and 
116.00±1.41 mg/dl (P<0.01) respectively. The reference control Glibenclamide 
also significantly (P<0.001) reduced the total cholesterol to 113.50±1.80 mg/dl. 
The effect produced by the ethanolic extract of Tephrosia purpurea is equipotent 
as that of the reference control. In the animals of normal control the triglyceride 
was 69.33±0.98 mg/dl, whereas the triglyceride was increased in diabetic control 
up to 115.83±2.70 mg/dl, The 200mg/kg of ethanol extract of Tephrosia Purpurea 
significantly (P<0.01) decreased by reversed the elevated triglyceride to 
89.17±2.24 mg/dl. Tephrosia purpurea, 400mg/kg and reference control 
glibenclamide, showed more significant (P<0.001) decrease in triglyceride level to 
74.50±1.20 and 73.50±1.95 mg/dl respectively.  
In the animals of normal control the HDL-Cholesterol was 36.67±1.28 
mg/dl, whereas it was decreased in hyperlipidemic control up to 22.83±1.01 
mg/dl. The 200mg/kg of ethanolic extract of Tephrosia purpurea showed 
moderate increase in HDL – Cholesterol compared to diabetic control. The 
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ethanolic extract of Tephrosia purpurea at 400mg/kg and the reference control 
glibenclamide significantly (P<0.001) enhanced the HDL – Cholesterol to the 
level of 32.67±0.49 and 31.17±1.09 respectively.  
In the animals of normal control the LDL-Cholesterol was 41.00±0.63 
mg/dl, where as it was increased in diabetic control up to 78.00±0.89 mg/dl. The 
200mg/kg of ethanolic extract of Tephrosia purpurea showed significant (P<0.01) 
decrease in LDL – Cholesterol compared to diabetic control. The ethanolic extract 
of Tephrosia purpurea at 400mg/kg and the reference control glibenclamide 
showed marked and significantly (P<0.001) decrease the LDL – Cholesterol to the 
level of 44.00±0.97 and 46.17±0.60 respectively. VLDL – Cholesterol levels in 
the normal animal was 17.67±0.88 mg/dl, where as in the diabetic control it was 
30.50±0.76 mg/dl. VLDL – Cholesterol (24.50±0.62 mg/dl) was significantly 
(P<0.05) decreased by 200mg/kg of ethanolic extract of Tephrosia purpurea.  The 
levels of VLDL – Cholesterol was more significantly (P<0.01) decreased by the 
treatment of 400mg/kg of Tephrosia purpurea and the reference control 
glibenclamide and the levels were 21.67±0.71 and 20.17±0.70 mg/dl.   
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Table 3. Mean ± SEM on lipid profile  
 
Values are in mean ± SEM (n=6), *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic 
Control 
 
 
Figure 5. Ethanolic extract of Tephrosia purpurea on lipid profile 
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Drug 
Treatment 
Lipid Profiles (mg/dl) 
Total 
Cholesterol 
Triglycerides HDL LDL VLDL 
 
Control 
1% CMC 
112.00± 
2.09*** 
69.33± 
0.98*** 
36.67± 
1.28*** 
41.00± 
0.63*** 
17.67± 
0.88*** 
 
Diabetic 
Control 
138.67±1.33 115.83±2.7 22.83± 
1.01 
78.00±0.89 30.50±0.76 
 
Reference 
Control 
113.50± 
1.80*** 
73.50± 
1.95*** 
31.17± 
1.09*** 
46.17± 
0.60*** 
20.17± 
0.70** 
 
TP 200 
125.67± 
2.20* 
89.17± 
2.24** 
27.83± 
0.91* 
59.33± 
0.42** 
24.50± 
0.62* 
 
TP 400 
116.00± 
1.41** 
74.50± 
1.20*** 
32.67± 
0.49*** 
44.00± 
0.97*** 
21.67± 
0.71** 
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Effect of Tephrosia purpurea on Liver Enzymes and Renal 
Functions 
 The effects of ethanolic extract of Tephrosia purpurea on Liver Serum 
Enzymes in STZ-Nicotinamide induced diabetes in rats were shown in the 
Table. No 4. The activity of AST, AST and ALT were significantly elevated in 
diabetic control rats compared to normal controls. Administration of ethanolic 
extract of Tephrosia purpurea at 200 mg/kg, significantly (P<0.01) reduced 
serum enzymes activity of ALT, and ALP to 8.12 ± 0.48 and 45.34 ± 0.61 IU/L 
respectively. It also significantly (P<0.05) the AST to 7.24 ± 0.28 IU/L 
compared to diabetic control.   Tephrosia purpurea at 400 mg/kg, significantly 
(P<0.001) reduced serum enzymes activity of ALT, and ALP to 5.59 ± 0.21 
and 39.36 ± 0.52 IU/L respectively. It also significantly (P<0.01) the AST to 
6.38 ± 0.20 IU/L compared to diabetic control. The reference control 
glibenclamide, showed significant (P<0.001) decrease in all the three serum 
liver enzymes as compare to diabetic control.  
 The effects of ethanolic extract of Tephrosia purpurea on serum BUN 
and Creatinine in STZ-Nicotinamide induced diabetes in rats and the results 
were shown in the Table. No 4. The Blood Urea Nitrogen and serum Creatinine 
were increased in the STZ – Nicotinamide induced diabetes animals as 
compared to normal control animals. Ethanolic extract of Tephrosia purpurea 
at 200 mg/kg, significantly (P<0.05) decrease the BUN (47.58 ± 0.46) and 
serum Creatinine (1.18 ± 0.04) as compared to diabetic control. Tephrosia 
purpurea at 400 mg/kg significantly (P<0.001) decrease both the BUN (32.67 
± 0.44) and serum Creatinine (0.77 ± 0.03) as compared to diabetes control.  
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The effect produced by Tephrosia purpurea 400 mg/kg on BUN and serum 
Creatinine was similar to that of Glibenclamide. 
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Table 4. Mean ± SEM on Liver and Renal Parameters  
Drug 
Treatment 
Liver Function Test Renal Function Test 
AST 
(IU/L) 
ALT 
(IU/L) 
ALP 
(IU/L) 
BUN 
(mg/dl) 
Creatinine 
(mg/dl) 
Control1% CMC 1.77 ± 0.08 4.89 ± 0.29 34.70 ± 0.58 21.65 ± 0.72 0.51 ± 0.03 
Diabetic Control 13.95 ± 0.43 10.02 ± 0.37 66.49 ± 0.43 50.88 ± 0.72 1.76 ± 0.01 
Reference Control 5.37 ± 
0.25*** 
5.99 ± 
 0.22*** 
38.54 ± 0.60*** 31.98 ±  
0.47*** 
0.65 ±  
0.02*** 
TP 200 8.12 ± 0.48** 7.24 ± 0.28* 45.34 ± 0.61** 47.58 ± 0.46* 1.18 ± 0.04* 
TP 400 5.59 ± 
0.21*** 
6.38 ± 
 0.20** 
39.36 ± 0.52*** 32.67 ±  
0.44*** 
0.77 ± 
 0.03*** 
 Values are in mean ± SEM (n=6),  *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic Control 
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Figure 6 – Effect of ethanolic extract of Tephrosia purpurea on Liver function test
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Figure 7 - Effect of ethanolic extract of Tephrosia purpurea on renal 
function test (BUN) 
 
Figure 8 - Effect of ethanolic extract of Tephrosia purpurea on renal 
function test (Creatinine) 
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7. DISCUSSION 
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DISCUSSION 
The present study was planned to evaluate the antidiabetic activity of 
ethanolic extract of Tephrosia purpurea against STZ – nicotinamide induced 
diabetes in rats. Administration of STZ and Nicotinamide has been proposed to 
induce experimental diabetes in rats.  STZ is well known to cause pancreatic B-
cell damage, whereas Nicotinamide is administered to rats to partially protect 
insulin-secreting cells against STZ. STZ is transported into B-cells via the 
glucose transporter GLUT-2 and causes DNA damage leading to increased 
activity of poly ADP-ribose polymerase (PARP-1). However, exaggerated 
activity of this enzyme results in depletion of intracellular NAD+ and ATP, and 
the insulin-secreting cells undergo necrosis. The protective action of 
nicotinamide is due to the inhibition of PARP-1 activity. Nicotinamide inhibits 
this enzyme, preventing depletion of NAD+ and ATP in cells exposed to STZ. 
Moreover, nicotinamide serves as a precursor of NAD+ and thereby 
additionally increases intracellular NAD+ levels. In vitro studies demonstrated 
that the insulin-secretory response to glucose is attenuated in STZ- 
nicotinamide induced diabetic rats compared with control animals. This is due 
to reduced β-cell mass as well as metabolic defects in the insulin-secreting 
cells4.  
 The ethanolic extract of Tephrosia purpurea reduced blood glucose 
level in STZ – nicotinamide induced diabetic rats. The biochemical mechanism 
of actions of Tephrosia purpurea extract might be due to an insulin mimetic 
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effect by either stimulating glucose uptake and metabolism, by inhibiting 
hepatic gluconeogenesis and glycogenolysis127, by stimulation of regeneration 
process or increase pancreatic secretion of insulin from existing β-cells and/ or 
inhibition activity against α-glucosidase enzymes in small intestine which 
convert disaccharides into monosaccharaides for sake of absorption128.  
 Tephrosia purpurea at the dose of 400mg/kg exhibited significant 
decrease in blood glucose level, as compared to 200mg/kg on 5th day of drug 
administration. The result was comparable with the standard drug 
glibenclamide which reduced fasting blood glucose level on same day. 
Moreover, both the doses of Tephrosia purpurea, showed significant blood 
glucose reduction in STZ – nicotinamide induced diabetic rats on day 10th, 15th 
and 30th days compared to diabetic control.  
 Phytochemical investigations on Tephrosia purpurea have reported the 
presence of phytoconstituents such as, glycosides, carotenoids, isoflavones, 
flavanones, chalcones, flavanols, and sterols101. It has also been suggested that, 
aqueous seed extract of Tephrosia purpurea has potent antihyperglycaemic and 
antioxidant effects in streptozotocin-induced diabetic rats107. Tremendous 
studies have found that flavonoids originated from foods could improve 
glucose metabolism, lipid profile, regulating the hormones and enzymes in 
human body, further protecting human being from diseases like obesity, 
diabetes and their complications129. In our findings, the antidiabetic activity 
exhibited by ethanolic extract of Tephrosia purpurea might be due to the 
presence of flavonoids in it.  
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 Abnormalities in lipid profile are common complications in diabetes 
mellitus. Such abnormality represents the risk factors for coronary heart 
diseases130. Activation of hormone sensitive lipase during insulin deficiency 
causes an increase in free fatty acid mobilization from adipose tissue. In 
addition, hyperglycaemia is accompanied by a rise in TC, TG, LDL-C and a 
fall in HDL-C131. In the present study, serum total cholesterol, triglycerides, 
LDL-C and VLDL - C levels were decreased and at the same time HDL-C was 
increased in Tephrosia purpurea extracts treated diabetic rats.  
The remarkable control of high serum triglycerides  in ethanolic extract 
of  Tephrosia purpurea treated diabetic rats could be due to inhibition of 
endogenous TG synthesis in liver or improvement in insulin level or the 
presence of active component(s) in Tephrosia purpurea that suppressed the 
activity of hormone sensitive lipase in adipose tissue or increased activity of 
hepatic lipase or lipoprotein lipase accountable for the hydrolysis of excess 
lipoprotein bound triacylglycerol into fatty acids109.  
Increased level of HDL-C in ethanolic extract of Tephrosia purpurea 
treated groups could be due to the enhancement of lecithin: cholesterol 
acyltransferase (LCAT) which plays a key role in incorporating the free 
cholesterol in to HDL which take back to the liver132. LDL-C reducing effect of 
Tephrosia purpurea presumably attributed to increased expression of low 
density lipoprotein receptor (LDLR), which enhance LDL particles uptake in 
liver from the circulation, through the depletion of intracellular cholesterol.  
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Serum total cholesterol lowering property of ethanolic extract of Tephrosia 
purpurea could be attributed to the presence of hypocholesterolemic 
compounds in Tephrosia purpurea that may act as inhibitor for hepatic 
hydroxyl methyl glutaryl CoA (HMG CoA) reductase in liver, which take part 
in cholesterol synthesis109. The decrease in serum total cholesterol, 
triacylglycerol, LDL-C and VLDL - C and an increase in HDL-C after 30 days 
treatment showed a dose dependent trend, indicating that efficacy was 
proportional to the dose of ethanolic extract of Tephrosia purpurea. In general, 
Tephrosia purpurea was capable to reverse the values of TC, TG, HDL-C and 
LDL-C, VLDL - C near normal after 30 days of treatment; this could be due to 
antioxidant property of Tephrosia purpurea. 
 The activity of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase (ALP) in serum are generally 
indicators for liver function. In diabetic rats, the levels of these enzymes are 
elevated due to the necrosis of liver cells by the injection of STZ – 
nicotinamide. However, Tephrosia purpurea treated diabetic rats showed 
decreased in the activity of ALT, AST and ALP enzymes that might support its 
hepatoprotective effect and normalization capability of impaired liver 
metabolism in diabetic rats111.  
 Negative nitrogen balance is manifested in diabetic rats associated with 
enhanced proteolysis in muscle and other tissues. Impaired balance of nitrogen 
coupled with lowered protein synthesis leads to increased concentrations of 
urea and creatinine in serum indicates progressive renal damage in diabetic 
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rats133. Treatment with ethanolic extract of Tephrosia purpurea resulted in a 
considerable reduction to near normal in BUN and creatinine level indicating 
the renoprotective role of Tephrosia purpurea or delay diabetic nephropathy 
development.  
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8. SUMMARY 
 
80 | P a g e  
 
SUMMARY 
This preclinical study was done to evaluate the anti-hyperglycaemic 
activity of whole plant extract of Tephrosia purpurea in STZ- Nicotinamide 
induced diabetic rats, which produced a significant difference in blood glucose, 
lipid profile, Renal and liver profile in comparison to untreated rats.  
 In this study, Wistar albino rats were divided into five groups containing 
six animals in each group. Diabetes is induced by administering STZ- 
Nicotinamide and fed with glucose water to prevent hypoglycaemia. Induced 
rats with blood sugar level >200 were enrolled in the study. Further the animals 
are grouped into Group I control (0.1% CMC), Group II Diseased control 
(STZ- Nicotinamide induced diabetes untreated rats) and treatment groups 
consists of Group III Glibenclamide group (STZ- Nicotinamide induced 
Diabetic rats treated with glibenclamide), Group IV and V STZ – Nicotinamide 
induced diabetic rats treated with Tephrosia purpurea extract 200mg/kg and 
400mg/kg respectively. All the animals were followed up for a period of one 
month. 
 Glibenclamide is an anti-diabetic drugs belongs to 2nd generation 
sulfonylurea, is well effective in the treatment of Diabetes mellitus is used as a 
reference control.  
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The study revealed the following findings: 
 In diabetic rats, treated with 200 and 400 mg/kg of Tephrosia purpurea 
blood glucose level significantly lowered to 157.17±5.55 on 10th day 
(P<0.05) and to 189.00±5.05 on 5th day (P<0.01) respectively as 
compared to untreated rats. At the end of 30th day there is significant 
reduction in blood glucose treated with TP 400mg/Kg 100.17±4.85    
( P <0.001). 
 Safety assessment shows the protective effect of TP (400mg/kg) on lipid 
profile TC 116±1.41 (P <0.01), TG 74.50 ± 1.20 (P <0.001), HDL 
32.67±0.49 ( P<0.001), LDL 44±0.97 ( P<0.001) and VLDL 21.67±0.71 
(P<0.01) . 
 It also shows protective activity against AST 5.59±0.21 (P<0.001), ALT 
6.38±0.20 (P<0.01), ALP 39.36±0.52 (P<0.001) and Renal functions 
BUN 32.67 ±0.44 (P<0.001) , Creatinine 0.77 ± 0.03 (P<0.001). For all 
safety parameters statistical values were highly significant. 
 
          The anti- hyperglycaemic activity of Tephrosia purpurea is 
brought out in the study by its significant reduction in the blood glucose 
level. The safety and efficacy is established based on the protective 
effect of Tephrosia purpurea in lipid profile, renal and hepatic function 
of diabetic rats. 
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9. CONCLUSION 
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CONCLUSION 
 In the present study, administration of ethanolic whole plant extract of 
Tephrosia purpurea to STZ – nicotinamide induced diabetic rats have 
significant reduction in blood glucose level, just about normalization of serum 
biochemical parameters including lipid profile (Total Cholesterol, 
Triglycerides, High density lipoprotein, low density lipoprotein and very low 
density lipoprotein), Serum liver enzymes (Alanine Aminotransferase, 
Aspartate Aminotransferase and Alkaline Phosphatase), Blood urea nitrogen 
and serum Creatinine compared to STZ – nicotinamide induced diabetic rats by 
similar mechanism as  glibenclamide, which involves insulin sensitization 
effect.   
 Consequently, it can be concluded that, Tephrosia purpurea exhibited 
antidiabetic activity in dose dependent manner against STZ – nicotinamide 
induced diabetes in Wistar albino rats thereby authenticating its ethno 
medicinal practice. From the observed antidiabetic activity of Tephrosia 
purpurea whole plant extract against STZ – nicotinamide induced diabetic rats, 
the study may supports the use of it for the management of diabetes mellitus 
and for the prevention of further complications. 
 
 
 
84 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. BIBLIOGRAPHY 
 
 
85 | P a g e  
 
BIBLIOGRAPHY 
 
1. Alberti KGMM, Zimmet PZ.  Definition, diagnosis and classification of 
diabetes mellitus and its complications. Part 1: diagnosis and 
classification of diabetes mellitus. Provisional report of a WHO 
Consultation. Diabet Med. 1998; 15: 539–553.  
 
2. Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V.  India towards 
diabetes control: Key issues. Australas Med J. 2013; 6(10):524-31.  
 
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes 
Care. 2004;27:1047–1053. 
 
4. Szkudelski T. Streptozotocin–nicotinamide-induced diabetes in the rat. 
Characteristics of the experimental model Exp Biol Med. 2012; 237(5): 
481 – 490. 
 
5. World Health Organization . Diabetes Mellitus: Report of a WHO Study 
Group. Geneva : WHO, 1985. Technical Report Series 727 
 
6. The Expert Committee on Diagnosis and Classification of Diabetes 
mellitus . Report of the expert committee on the Diagnosis and 
classification of Diabetes mellitus. Diabetes Care 2010;20:1183-97 
 
86 | P a g e  
 
 
7. Ghalioungui P. The Ebers papyrus: A new English translation, 
commentaries and glossaries. Cairo: Academy of Scientific  Research and 
Technology, 1987 
 
8. Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, Poulakou-
Rebelakou E. Milestones in the history of diabetes mellitus: World J 
Diabetes. 2016; 7(1): 1-7. 
 
9. Furdell EL. Fatal Thirst. Diabetes in Britain until Insulin. Leiden: Brill, 
2009: 81-92 
 
10.  Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose 
homeostasis. Experimental & Molecular Medicine. 2016;48(3):e219-.  
 
11. Von Mering J, Minkowski O. Diabetes mellitus nach Pankreas 
extirpation. Arch f exper Path u Pharmakol. 1889; 26: 371. 
 
12. Cooper T, Ainsberg A. Breakthrough: Elizabeth Hughes, the Discovery of 
Insulin, and the Making of a Medical Miracle. New York: St Martin’s 
Press, 2010. 
 
 
87 | P a g e  
 
13. Quianzon CCL, Cheikh IE. History of current non-insulin medications for 
diabetes mellitus. J Community Hosp Intern Med Perspect. 2012; 
2(3):10.3402/jchimp.v2i3.19081.  
 
14.  Ramachandran A, Snehalatha C. API text book of medicine ,10th Edition. 
The Association of Physicians . Mumbai. Munjal Y ; 2015 
 
15. Bailey C, Day C. Metformin: Its botanical background. Pract Diab 
Int.2004; 21: 115-117.  
 
16. White JR: Overview of the medications used to treat type 2 diabetes. In 
Medications for the Treatment of Diabetes. White JR, Campbell RK, Eds. 
Alexandria. Va., American Diabetes Association. 2008; 5–15. 
 
17. Golan David E, Tashjian Jr Armen H, Armstrong Ehrin J, Armstrong 
April W. Principles of Pharmacology .3rd edition. New Delhi: wolters 
kluwer India Pvt Ltd; 2012. 
 
18. Global action plan for the prevention and control of non-communicable 
diseases 2013-2020. Geneva: World Health Organization; 2013. 
 
19. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in 
India. AMJ 2014; 7(1):, 45-48. 
 
88 | P a g e  
 
20. Kasper, D., Fauci, A., Hauser, S., Longo, D., & Jameson, J. 
(2015). Harrison's Principles of Internal Medicine. New York: McGraw-
Hill Education. 
 
21. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren 
NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in 
insulin-dependent diabetes mellitus. J Clin Invest. 1992; 89: 283-292. 
 
22. Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants 
in NIDDM. Diabet. 1989; 38: 784-792. 
 
23. Wang Y, Lobstein T. Worldwide trends in childhood overweight and 
obesity. Int J Ped Obes. 2006; 1: 11-25. 
 
24. Rizza RA, Gerich JE, Haymond MW. Control of blood sugar in insulin-
dependent diabetes: Comparison of an artificial endocrine pancreas, 
continuous subcutaneous insulin infusion, and intensified conventional 
insulin therapy. N Engl J Med. 1980; 303: 1313-1318. 
 
25. Consoli A, Kennedy F, Miles J, Gerich J. Determination of Krebs cycle 
metabolic carbon exchange in vivo and its use to estimate the individual 
contributions of gluconeogenesis and glycogenolysis to overall glucose 
output in man. J Clin Invest. 1987; 80: 1303-1310. 
 
89 | P a g e  
 
 
26. Meyer C, Nadkarni V, Stumvoll M, Gerich J. Human kidney free fatty 
acid and glucose uptake: Evidence for a renal glucose-fatty acid cycle. 
Amj J Physiol. 1997; 273: E606-E612.  
 
27. Oster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced 
hyperglycaemia on gastric emptying rate in healthy humans. Scand J Clin 
Lab Invest. 1990; 50: 831-836. 
 
28. Meyer C, Dostou J, Nadkarni V, Gerich J. Effects of physiological 
hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. 
Am J  Physiol Renal Physiol. 1998; 275: F915-F921. 
 
29. Goodman, L. S., Brunton, L. L., Chabner, B., & Knollmann, B. C. 
(2011). Goodman & Gilman's pharmacological basis of therapeutics. 
New York: McGraw-Hill. 
 
30. Lecavalier L, Bolli G, Cryer P, Gerich J. Contributions of 
gluconeogenesis and glycogenolysis during glucose counter regulation in 
normal humans. Am J Physiol Endocrinol Metab. 1989; 256. 
 
 
 
90 | P a g e  
 
31. De Feo P, Perriello G, Torlone E, Fanelli C, Ventura MM, Santeusanio F, 
Brunetti P, Gerich JE, Bolli GB. Contribution of adrenergic mechanisms 
to glucose counter regulation in humans. Am J Physiol Endocrinol Metab. 
1991; 261: E725–E736. 
 
32. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and 
NIDDM. Diabetes. 1997; 46: 3-10. 
 
33. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The 
pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus, 
J Physiol Pathophysiol. 2013; 4(4): 46-57. 
 
34. Froguel P, Velho G. Genetic determinants of type 2 diabetes. Recent Prog 
Horm Res. 2001; 56: 91-105. 
 
35. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - 
A genetically programmed failure of the beta cell to compensate for 
insulin resistance. N Engl J Med. 1996; 334: 777-783. 
 
36. Kahn SE. The importance of the β-cell in the pathogenesis of type 2 
diabetes mellitus. Am J Med. 2000; 108: 2-8. 
 
 
91 | P a g e  
 
37. Leahy JL, Bonner-Weir S, Weir GC. β-Cell dysfunction induced by 
chronic hyperglycemia: Current ideas on mechanism of impaired glucose-
induced insulin secretion. Diabetes Care. 1992; 15: 442-455. 
 
38. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, 
Taborsky GJ, Jr, Porte D. Jr. Evidence of cosecretion of islet amyloid 
polypeptide and insulin by β-cells. Diabetes 1990; 39: 634-638. 
 
39. Clark A, Saad MF, Nezzer T. Islet amyloid polypeptide in diabetic and 
non-diabetic Pima Indians. Diabetologia. 1990; 33: 285-289. 
 
40. Porte Jr D, Kahn ESE. β-cell dysfunction and failure in type 2 diabetes: 
Potential mechanisms. Diabetes. 2001; 50: S160-S163. 
 
41. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, 
Eschwege E. Risk factors for NIDDM in white population: Paris 
prospective study. Diabetes. 1991; 40: 796-799. 
 
42. Kolterman OG, Gray RS, Griffin J. Receptor and postreceptor defects 
contribute to the insulin resistance in noninsulin-dependent diabetes 
mellitus. J  Clin Invest. 1981; 68: 957-969. 
 
 
92 | P a g e  
 
43. Roden M, Stingl H, Chandramouli V. Effects of free fatty acid elevation 
on postabsorptive endogenous glucose production and gluconeogenesis in 
humans. Diabetes. 2000; 49: 701-707. 
 
44. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 
1990; 13: 610-630. 
 
45. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty 
years of personal experience in hyperglycemic crises: diabetic 
ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol 
Metab. 2008; 93: 1541 – 1552. 
 
46. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflamatory 
cytokines, markers of cardiovascular risks, oxidative stress, and lipid 
peroxidation in patients with hyperglycemic crises. Diabetes. 2004; 53: 
2079 – 2086. 
 
47. Hansen TK, Moller N. Acute Metabolic Complications of
 Diabetes: Diabetic Ketoacidosis and Hyperosmolar Hyperglycemia. In 
Textbook of diabetes 4th Edition. 2010. 
 
 
93 | P a g e  
 
48. Keller U, Szinnai G, Bilz S, Berneis K. Effects of changes in hydration on 
protein, glucose and lipid metabolism in man: impact on health. Eur J 
Clin Nutr. 2003; 57 (2): S69 – S74. 
 
49. Moller N, Foss AC, Gravholt CH, Mortensen UM, Poulsen SH, 
Mogensen CE. Myocardial injury with biomarker elevation in diabetic 
ketoacidosis. J Diabetes Complications. 2005;19(6):361–363. 
 
50. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the 
elderly. Med Clin North Am. 2004; 88: 1063 – 1084. 
 
51. Fowler MJ. Microvascular and macrovascular complications of diabetes. 
Clin Diabetes. 2008; 26(2):77-82. 
 
52. Tripathi BK, Srivastava AK, (2006). Diabetes mellitus: Complications 
and therapeutics. Med Sci Monit. 2006; 12(7): RA130-147. 
 
53. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK and Won NH. 
(2000). Role of vascular endothelial growth factor in diabetic 
nephropathy. Kidney Inter. 2000; 58 (77): S104–S112. 
 
 
94 | P a g e  
 
54. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W.  
Ethnicity, race, and baseline retinopathy correlates in the Veterans Affairs 
Diabetes Trial. Diabetes Care. 2005; 28: 1954 – 1958. 
 
55. Gardiner TA, Archer DB, Curtis TM, Stitt AW. Arteriolar involvement in 
the microvascular lesions of diabetic retinopathy: implications for 
pathogenesis. Microcir. 2007; 14: 25 – 38. 
 
56. Bunce C, Wormald R. Leading causes of certification for blindness and 
partial sight in England and Wales. BMC Public Health. 2006; 6: 58. 
 
57. Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic 
neuropathy. In: Gries F.A., Cameron N.E., Low P.A. and Ziegler D. Eds. 
Textbook of Diabetic Neuropathy. Stuttgart/New York: Thieme. 2003; 64 
– 82. 
 
58. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM.  
Multicenter study of the incidence of and predictive risk factors for 
diabetic neuropathic foot ulceration. Diabetes Care. 1998; 21: 1071 – 
1075. 
 
 
95 | P a g e  
 
59. Sorensen L, Molyneaux L, Yue DK. (2006). The relationship among pain, 
sensory loss, and small nerve fibers in diabetes. Diabetes Care.2006;  29: 
883–887. 
 
60. Marchettini P, M Lacerenza, E Mauri, C Marangoni. Painful Peripheral 
Neuropathies. Curr Neuropharmacol. 2006; 4(3): 175–181. 
 
61. Dash PC, Barik C, Sethy S, Dash KC. Relationship of Carotid Intima 
Media Thickness with Silent Cerebral Infarction in Patients of Type 2 
Diabetes Nephropathy. Int J Rec Sci Res.  2017; 8(7): 18247-18252. 
 
62. Giorgino F, Laviola L, Perin CP, Solnica B, Fuller J. Chaturvedi N. 
Factors associated with progression to macroalbuminuria in 
microalbuminuric type 1 diabetic patients: the EURODIAB prospective 
Complications Study. Diabetologia. 2004; 47: 1020 – 1028. 
 
63. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. 
Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic 
threshold. Kidney Int. 2001; 60: 219 – 227. 
 
64. Bieke F. Schrijvers, Allan Flyvbjerg, An S. De Vriese, The role of 
vascular endothelial growth factor (VEGF) in renal pathophysiology. 
Kidney International. 65, (6), 2004, 2003-2017. 
 
96 | P a g e  
 
 
65. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long -term 
follow - up after tight control of blood pressure in type 2 diabetes. N Engl 
J Med. 2008; 359: 1565 – 1576. 
 
66. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A,  Alwell K. 
Epidemiology of ischemic stroke in patients with diabetes: the Greater 
Cincinnati and Northern Kentucky Stroke Study. Diabetes Care. 2004; 
28: 355 – 359. 
 
67. Beauchamp MC, Michaud SE, Li L, Sartippour MR, Renier G. Advanced 
glycation end products potentiate the stimulatory effect of glucose on 
macrophage lipoprotein lipase expression. J Lipid Res. 2004; 45: 1749 – 
1757. 
 
68. Libby P. Current concepts of the pathogenesis of the acute coronary 
syndromes. Circulation. 2001; 104: 365 – 372. 
 
69. Cooper R, Cutler J, Desvigne- Nickens P, Fortmann SP, Friedman L, 
Havlik R. Trends and disparities in coronary heart disease, stroke, and 
other cardiovascular diseases in the United States: findings of the national 
conference on cardiovascular disease prevention. Circulation. 2000; 102: 
3137 – 3147. 
 
97 | P a g e  
 
 
70. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection- 
related mortality in the United States. Diabetes Care. 2001; 24: 1044 – 
1049. 
 
71. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with 
diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999; 26: 259 – 
265. 
 
72. Cockram CS, Lee N. Diabetes and infections. In Holt RIG, Cockram CS, 
Flyvbjerg  A, Goldstein BJ. (eds). Textbook of Diabetes, 4th Edition. 
John Wiley and Sons Ltd. 2010. 
 
73. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. 
Severe bloodstream infections: a population - based assessment. Cri Care 
Med; 2004; 32: 992 – 997. 
 
74. Katzung Bertram G, Masters Susan B, Trevor Anthony J. Basic and 
Clinical Pharmacology. 13th edn. New York: Mc Graw Hill medical ; 
2015. 
 
 
98 | P a g e  
 
75. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y.  Drug-induced 
hypoglycemic coma in 102 diabetic patients. Arch  Int Med. 1999; 159: 
281-284. 
 
76. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is 
combination sulfonylurea and insulin therapy useful in NIDDM patients: 
A metaanalysis. Diabetes Care. 1992;  15: 953-959. 
 
77. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom 
Prospective Diabetes Study perspective. Metabolism: Clinical and 
Experimental. 2006; 55: S2-S5. 
 
78. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial 
infarction and death from cardiovascular causes. N Eng J Med. 2007; 
356: 2457-2471. 
 
79. Luft D, Schmuelling RM, Eggstein M. Lactic acidosis in biguanide-
treated diabetics. A review of 330 cases. Diabetologia. 1978; 14: 75-87. 
 
80. Hamilton MT, Booth FW. Skeletal muscle adaptation to exercise: A 
century of progress. J Appl Physiol. 2000; 88: 327-331. 
 
 
99 | P a g e  
 
81. Swanston-Flatt SK, Flatt PR, Day C, Bailey CJ. Traditional dietary 
adjuncts for the treatment of diabetes mellitus. Proceed Nutr Soci. 1991; 
50: 641-651. 
 
82.  Bailey CJ, Turner RC. Metformin. N Eng J  Med. 1996; 334: 574-579 . 
 
83. Iranloye BO, Arikawe AP, Rotimi G, Sogbade AO. Anti-diabetic and 
anti-oxidant effects of Zingiber officinale on alloxan-induced and insulin-
resistant diabetic male rats. Nigerian journal of physiological sciences : 
official publication of the Physiological Society of Nigeria 
2011;26(1):89-96.  
 
84. Herr RR, Jahnke JK, Argoudelis AD. The structure of streptozotocin. J 
Am Chem Soci. 1967;89(18):4808-9.  
 
85. Mythili MD, Vyas R, Akila G, Gunasekaran S. Effect of streptozotocin 
on the ultrastructure of rat pancreatic islets. Micro Res Tech. 
2004;63(5):274-81.  
 
86. Epand RM, Stafford AR, Tyers M, Nieboer E. Mechanism of action of 
diabetogenic zinc-chelating agents. Model system studies. Mol 
Pharmacol. 1985;27(3):366-74.  
 
 
100 | P a g e  
 
87. Karasawa H, Takaishi K, Kumagae Y. Obesity-induced diabetes in mouse 
strains treated with gold thioglucose: a novel animal model for studying 
β-cell dysfunction. Obes. (Silver Spring, Md.) 2011;19(3):514-21.  
 
88. Nagata M, Suzuki W, Iizuka S, Tabuchi M, Maruyama H, Takeda S. 
Type 2 diabetes mellitus in obese mouse model induced by monosodium 
glutamate. Exp Ani Jap Asso Lab Ani Sci. 2006;55(2):109-15.  
 
89. Gamble DR, Kinsley ML, FitzGerald MG, Bolton R, Taylor KW. Viral 
antibodies in diabetes mellitus. Bri Med J. 1969;3(5671):627-30. 
 
90.  Utsugi T, Kanda T, Tajima Y, Tomono S, Suzuki T, Murata K. A new 
animal model of non-insulin-dependent diabetes mellitus induced by the 
NDK25 variant of encephalomyocarditis virus. Diabetes Res (Edinburgh, 
Scotland) 1992;20(4):109-19.  
 
91. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. 
Diabetes induced by Coxsackie virus: initiation by bystander damage and 
not molecular mimicry. Nature medicine 1998;4(7):781-5.  
 
92. Campbell J, Chaikof L, Davidson IWF. Metahypophyseal diabetes 
produced by growth hormone. Endocrinol 1954:48-58.  
 
101 | P a g e  
 
93. Heather A, Ferris C, Kahn R. New mechanisms of glucocorticoids-
induced insulin resistance: make no bones about it. J Clin Invest. 
2012;122: 3854-57.  
 
94. Gould CL, McMannama KG, Bigley NJ, Giron DJ. Virus-induced murine 
diabetes. Enhancement by immunosuppression. Diabetes. 
1985;34(12):1217-21.  
 
95. Nadkarni KN, Nadkarni AK, The indian material medica, popular 
prakashan,1,200, 561. 
 
96. Warrier PK, Nambiar VPK, Ramankutty C. Indian Medicinal Plants. Vol-
1.Oriant Longman Ltd; Arya Vaidya Sala: Kottakkal, 2000; 249 - 251.  
 
97. Sharma R, Mehan S, Kalra S, Khanna D Tephrosia purpurea – A Magical 
Herb With Blessing In Human Biological System.  Int J Recent Advan In 
Pharmal Res. 2013; 3(3): 12-22. 
 
98. Chopra RN, Nayer SL, Chopra IC “Glossary of Indian Medicinal Plants”, 
Council of Scientific and Industrial Research, New Delhi, India. 1956-92; 
I: 241. 
 
 
102 | P a g e  
 
99. Deshpande SS, Shah GB. “Pharmacological activity of Tephrosia 
purpurea”, Am Asso Pharm Scient J, 2003;10: 55-59. 
 
100. Kumari S, Srivastava M, Abbasi P. Response of Tephrosia purpurea to 
salinity stress in relation to germination, carotenoid content and proline 
content. An Int Quart J Biol  Life Sci. 2014;  2:  276-281.  
 
101. Chaudhari TB, Tambe DA, Chaudhari SR. Phytopharmacology of 
Tephrosia purpurea Pers. (Fabaceae). IJPI’s J Pharmacog Herb Form. 
2012; 2(8):1-13. 
 
102. Chang LC, Chavez D, Song LL, Farnsworth NR, Pezzuto JM, Kinghorn 
AD. Absolute configuration of novel bioactive flavonoids from Tephrosia 
purpurea .Org Lett. 2000; 2: 515- 518. 
 
103. Venkata Rao E, Ranga Raju N. Two flavonoids from Tephrosia 
purpurea. Phytochem. 1984;23(10): 2339- 2342. 
 
104. Gupta RK, Krishnamurti M, Parthasarathi J. A new flavanone from 
Tephrosia purpurea seeds. Phytochem. 1980; 19: 1264. 
 
 
 
103 | P a g e  
 
105. Pavana P, Manoharan S, Renju GL, Sethupathy S.Antihyperglycemic 
and antihyperlipidemic effects of Tephrosia purpurea leaves extract in 
streptozotocin induced diabetic rats. J  Environ Biol. 2007; 28(4):833-
837. 
 
106. Hutchings A, van Staden J. Plants used for stress-related ailments in 
traditional Zulu, Xhosa and Sotho medicine. Part 1: Plants used for 
headaches. J Ethnopharmacol. 1994; 43(2):89-124. 
 
107. Pavana P, Sethupathy S, Santha K, Manoharan S. Effects of Tephrosia 
purpurea aqueous seed extract on blood glucose and antioxidant enzyme 
activities in streptozotocin induced diabetic rats. Afr J Trad CAM. 2009; 
6 (1): 78-86. 
 
108. Pavana P, Sethupathy S, Manoharan S. Antihyperglycemic and 
antilipidperoxidative effect of TP seed extract in streptozotocin induced 
dibetic rats. Ind J  Clin Biochem. 2007; 22 (1) 77-83.  
 
109. Sayad mustak. Comparative study of Tephrosia purpurea (Linn) leaves 
and Lovastatin on cholesterol level of hyperlipidemic wistar rats. IOSR J 
Pharm Biol Sci. 2012;1(2):25-30. 
 
 
104 | P a g e  
 
110. Sangeetha B, Krishnakumari S. Folk Medicinal plant Tephrosia 
purpurea ameliorates carbon tetrachloride induced hepatic damage in 
rats. Int J  Pharma Biosci.2010;1(2):1-10. 
 
111. Khatria A, Gargb A, Shyam S Agrawal. Evaluation of hepatoprotective 
activity of aerial parts of Tephrosia purpurea L. and stem bark of 
Tecomella undulate. J Ethnopharmacol. 2009; 122: 1–5. 
 
112. Manjula RR, Spandana U, Joshi Anand T, Sudheer M. In vitro 
anthelmintic activity of aqueous and methanolic leaf extract of Tephrosia 
purpurea linn. Int J Res Pharm  Chem. 2013;3(1):12-14. 
 
113. Ashok kumar D, Narayana TV, Vidyasagar, Mazumder UK, Gupta M. 
Exploration of diuretic potential and electrolyte excretion of Tephrosia 
purpurea (Fabaceae) in rats. J Diet Sup. 2012;9(1):9-18. 
 
114. Gopalakrishnan S, Vadivel E, Dhanalakshmi K. Antiinflammatory and 
analgesic activities of Tephrosia purpurea Linn. Aerial and root extracts. 
J Pharm Res. 2010; 3(5): 1103-1106. 
 
115. Rumit Shah, Heena Kathad, Rajal Sheth, Naveen Sheth. In vitro 
antioxidant activity of roots of Tephrosia purpurea linn. Int J Pharm 
Pharmaceu Sci. 2010; 2(3): 30-33. 
 
105 | P a g e  
 
 
116. Damre AS, Gokhale AB, Phadke AS, Kulkarni KR, Saraf MN. Studies 
on the immunomodulatory activity of flavonoidal fraction of Tephrosia 
purpurea . Fitoterap. 2003; 74: 257-261. 
 
117. Soria B, Quesada I, Ropero AB, Pertusa JA, Martin F, Nadal A. Novel 
players in pancreatic islet signaling: from membrane receptors to nuclear 
channels. Diabetes. 2004;53 (Suppl 1):S86–91. 
 
118. Hatou S, Yamada M, Akune Y, Mochizuki H, Shiraishi A, Joko T, 
Nishida T, Tsubota K. Role of insulin in regulation of Na+-/K+-
dependent ATPase activity and pump function in corneal endothelial 
cells. Invest Ophthalmol Vis Sci. 2010 ;51(8):3935-42 
 
119. Roeschlau P, Bernt E, Gruber WA Enzymatic determination of total 
cholesterol in serum. Clin Biochem. 1974; 12: 226-228. 
 
120. Tietz NW. Clinical guide to laboratory tests. 2nd ed. W.B. Saunders  
Company, Philadelphia. 1990. 
 
121. Lopes-Virella MF, Stone P, Ellis S,  Colwell JS.  Cholesterol 
determination in high density lipoproteins separated by three different 
methods. Clin Chem. 1977; 23: 882-884.  
 
106 | P a g e  
 
 
122. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without 
use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.  
 
123. Reitman S, Frankel S. A colorimetric method for the determination of 
serum glutamic oxaloacetic and glutamic pyruvic  transaminases. Am J 
Clin Pathol. 1957; 28: 56 - 63.  
 
124. King EJ. Assay of acid and alkaline phosphatase. In Practical Clinical 
Enzymology (D. Van Nostrand Co., London). 1965; 85-87. 
 
125. Natelson S, Scott ML, Beffa C. A rapid method for the estimation of 
urea in biological fluid by means of the reaction between diacetyl-
monoxime and urea. Am J Chem Pathol. 1951; 21: 275. 
 
126. Slot C. Plasma creatinine determination: a new and specific Jaffe 
reaction method. Scand J Clin Invest. 1965; 17: 381. 
 
127. Daisy P, Balasubramanian K, Rajalakshmi M, Eliza J, Selvaraj J.  
Insulin mimetic impact of Catechin isolated from Cassia fistula on the 
glucose oxidation and molecular mechanisms of glucose uptake on 
Streptozotocin induced diabetic Wistar rats. Phytomed. 2010;17: 28-36. 
 
107 | P a g e  
 
 
128. Shinde J, Taldone  T, Barletta M, Kunaparaju N, Hu B, Kumar S, 
Placido J, Zito SW. α-Glucosidase inhibitory activity of Syzygium cumini 
(Linn.) Skeels seed kernel in vitro and in Goto–Kakizaki (GK) rats. 
Carbohydrate Res. 2008; 343: 1278-1281. 
 
129. Vinayagam R, Xu B. Antidiabetic properties of dietary flavonoids: A 
cellular mechanism review. Nutr  Metab. 2015; 12:60. 
 
130. Shamaony LA, Khazraji SMA, Twaij HAA. Hypoglycaemic effect of 
Artemisia herba alba. II. Effect of a valuable extract on some blood 
parameters in diabetic animals. J Ethnopharmacol. 1994; 43: 167-171. 
 
131. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Clin 
Prac Endocrinol & Metab. 2009; 5, 150-159. 
 
132. Ghatak SB, Panchal SJ. Anti-hyperlipidemic activity of oryzanol, 
isolated from crude rice bran oil, on Triton WR-1339-induced acute 
hyperlipidemia in rats. Braz J Pharmacog. 2012; 23, 642-648. 
 
133. Rumit S, Kathad H, Sheth R, Sheth N. In vitro antioxidant activity of 
roots of Tephrosia purpurea linn.  Int J Pharm Pharmaceu Sci. 2010; 2(3), 
30-33.  
 
108 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. ANNEXURES 
 
109 | P a g e  
 
ANNEXURE I 
 
 
 
110 | P a g e  
 
ANNEXURE II 
 
 
111 | P a g e  
 
ANNEXURE II A 
 
 
 
 
 
 
 
 
 
112 | P a g e  
 
ANNEXURE III
 
